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ABSTRACT 
 
Probiotics and prebiotics are used widely because of their benefits to digestive 
and immune health. While there is significant evidence to support their effectiveness in 
humans and livestock animals, interpretation of the results of this research is compli-
cated by the wide differences in research. We have explored host-specific digestive 
physiology, experimental constraints, and probiotic and prebiotic functionality. The in-
sight provided by an understanding of these important differences will provide a context 
in which results of host-specific studies and their broader implications to the science can 
be evaluated.  
Lactobacillus species are common inhabitants of the gastrointestinal tract and are 
widely used as probiotics because of their health promoting benefits. When used as Di-
rect Fed Microbials (DFM) in poultry, they have been demonstrated to promote growth, 
stimulate immune responses, and reduce intestinal colonization of pathogens. While they 
are used widely, the mechanisms responsible for their functionality are not well under-
stood. While genetic tools available for use in lactobacilli are advanced, they have not 
been applied to investigate the probiotic functionality of Lactobacillus cultures in poul-
try. The objective of this study is to demonstrate the functionality of the pORI28 system 
in L. gallinarum ATCC 33199 by insertional inactivation of lacL, encoding β-galacto-
sidase. The establishment of an effective chromosomal integration system for L. galli-
narum will provide a platform for functional genomic analyses to investigate the func-
tionality of this model probiotic culture in poultry. 
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DFM and exogenous enzymes have been demonstrated to improve growth per-
formance in poultry and are potentially important alternatives to antibiotic growth pro-
moters (AGP). We investigated the administration of a feed additive composed of a 
DFM products and enzymes in broiler chickens over a 42-day growth period. Evaluation 
of growth performance determined feed efficiency of broiler chickens which were ad-
ministered the feed additive was comparable to those fed a diet containing AGPs. Char-
acterization of the gastrointestinal microbiota using culture-dependent methods deter-
mined administration of the feed additive increased or decreased counts of bacteria enu-
merated from the gastrointestinal tract of the broiler chicken. Our results suggest the ad-
ministration of DFMs and exogenous enzymes may potentially be an important compo-
nent of antibiotic free poultry production. 
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1. INTRODUCTION: PERSPECTIVES ON DIFFERENCES BETWEEN HUMAN
AND LIVESTOCK ANIMAL RESEARCH IN PROBIOTICS AND PREBIOTICS1 
1.1 INTRODUCTION 
Research in the application of probiotics and prebiotics in human and animal 
health has grown due to the increased interest in the gastrointestinal microbiota. The mi-
crobial community present in the gastrointestinal tract is thought to play an important 
role in host animal health and is a potentially important therapeutic target that can be 
manipulated in order to achieve positive health outcomes. Thus, the use of probiotics and 
prebiotics represents a powerful strategy for the manipulation of the microbial commu-
nity in the gastrointestinal tract (1-4). 
Probiotics are live microorganisms, which when administered in adequate 
amounts confer a health benefit on the host (5), and prebiotics are selectively fermented 
ingredients that result in specific changes in the composition and/or activity of the gas-
trointestinal microbiota conferring benefit(s) upon host health (6). The benefits of probi-
otic and prebiotic application in humans and animals include inhibition of pathogens (7, 
8), improved digestive function (9, 10), and modulation of immune responses (11-13). In 
animal agriculture, probiotics and prebiotics are thought to be an important potential al-
1 Reprinted with permission, Tyler Edward Askelson and Tri Duong. “Chapter 30. Perspectives on Differ-
ences Between Human and Livestock Animal Research in Probiotics and Prebiotics.“ Probiotics and Prebi-
otics: Current Research and Future Trends. Ed. Koen Venema, Ed. Ana Paula do Carmo. Norfolk: Caister 
Academic Press, 2015. 447-458. Print. 
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ternative to the use of antibiotic growth promoters (AGP) (14, 15). When used in live-
stock, they have been demonstrated to promote growth performance at levels similar to 
AGPs (16, 17) and reduce gastrointestinal colonization by pathogens (18).  
The benefits of probiotic and prebiotic use in humans and livestock animals have 
been well demonstrated (Table 1.1). However, the overall effectiveness of their applica-
tion is thought to be mixed (19), and results of their use in livestock animals are per-
ceived by some to be superior when compared to humans. A direct comparison of the 
overall effectiveness of probiotics and prebiotics between studies in humans and live-
stock animals, and between livestock animal species, is complicated by differences in 
the digestive physiology of the host animal, experimental constraints, and the desired ex-
perimental outcomes. Indeed, such a direct comparison may be inappropriate and irrele-
vant. An appreciation of host-specific differences and interpretation of research in this 
context will allow host-specific studies to contribute to an improved understanding of 
probiotic and prebiotic functionality for application in both human and animal health 
  
 3 
 
  
Table 1.1. Examples of probiotic and prebiotic benefits 
Type References 
Digestion 
Human 
 
(20) 
(21) 
(22) 
Chicken 
 
(23) 
(24) 
Cattle 
 
(25) 
(26) 
(27) 
Pathogen Inhibition 
Human 
 
(28) 
(29) 
Pig (18) 
Chicken (30) 
Immunomodulation 
Human (31) 
(13) 
(32) 
Pig (12) 
Chicken (33) 
Cattle (34) 
(27) 
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1.2 DIGESTIVE PHYSIOLOGY AND MICROBIOLOGY 
The autochthonous gastrointestinal microbiota of humans and animals is complex 
and dynamic with hundreds of microbial species coexisting in a web of interdependency 
and antagonism, both with each other and the host animal (35-37). Host factors including 
age (38, 39) and diet  (38, 40) have been demonstrated to affect the composition of the 
gastrointestinal microbiota. Thus, introduction of allochthonous microbial species or 
specific dietary components to these already complex environments can cause shifts in 
the composition of the microbial community (41, 42) and potentially produce beneficial 
or negative effects on the host animal.  
1.2.1 Ruminant and Monogastric Animals. 
The anatomic features and physiology of the digestive tract vary widely between 
humans, swine, cattle, and chickens (Figure 1.1). As a result of these host-animal adap-
tations to dietary niches, not only is the gastrointestinal microbial community signifi-
cantly different between species (37, 43), but the digestive organs of primary research 
interest is species-specific as well (Table 1.2). While the predominant bacterial genera 
may be similar between host animal species, the microorganisms vary at the species and 
subspecies levels (44, 45). Variation in the composition of the gastrointestinal microbial 
community between individuals of the same species is also significant (38). Thus, it is 
important to consider the interactions of probiotic cultures and prebiotics with the host-
animal, the autochthonous microbiota, and the nutrition of the host animal. 
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Figure 1.1. Digestive anatomy. Anatomic features of the human, pig, chicken, and cat-
tle. [Human and chicken adapted from Comparative Physiology of the Vertebrate Diges-
tive System with the permission of Cambridge University Press. Copyright (1995) Cam-
bridge University Press. Pig adapted from the American Journal of Physiology (46). 
Copyright 1976 American Physiological Society]. 
 
 
Cow
(Bos primigenius)
Body Length:  240 cm
1000 cm
Chicken
(Gallus domesticus)
Body Length:  46 cm
Adult Human
(Homo sapiens)
Body Length:  180 cm
Pig
(Sus scrofa)
Body Length:  125 cm
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Table 1.2. Features of relevant digestive organs* 
Host Organ Cells g-1 or 
Cells mL-1 
Organ 
Contents 
References 
Human Colon 3.2 × 1011 220 g (47) 
(48) 
Pig Colon 5.4 × 1010 9 L (49) 
(50)  Cecum 2.8 × 1010 1 L 
Chicken Cecum 9.5 × 1010 2 g (51) 
Cattle Rumen 2.1 × 1010 106 L (52) 
(53) 
*Adapted from Proceedings of the National Academy of Sciences of the United States of 
America (54) with permission of the publisher. Copyright (1998) National Academy of 
Sciences, U.S.A. 
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The microbiota of cattle and other ruminant animals is considerably complex 
(55) when compared with monogastric animals. The bovine rumen is populated by mi-
croorganisms which ferment indigestible plant material producing volatile fatty acids 
(VFA) and microbial crude protein for absorption by the host animal (55). The predomi-
nant microorganisms found in the rumen include the Firmicutes Butyrvibrio and Rumi-
nococcus and the Bacteroidete Prevotella (37), while the predominant microorganisms 
of the lower intestines include strict anaerobic species from the genera Bifidobacterium, 
Clostridium, and Bacteroides (56). Additionally, differences in microbial composition of 
the rumen have been demonstrated between beef and dairy cattle. Beef cattle are popu-
lated by greater numbers of cellulytic bacteria including Fibrobacter, Ruminococcus, 
and Succiniclasticum, likely reflecting the need for greater fiber digestion of hay-fed 
beef cattle (37, 38). While Prevotella are the most abundant genus in the rumen of cattle, 
they are present in lower abundance in beef cattle than in  dairy cows (38). 
Differences between chickens, humans, and swine demonstrate interspecific vari-
ation in the gastrointestinal microbiota of monogastric animals. The chicken ileum is 
populated largely with Lactobacillus, followed distantly by Clostridium and Enterococ-
cus, while Clostridium is more prevalent than Lactobacillus in the cecum (44). In mo-
nogastric mammals, the human intestinal tract is dominated by Bacteroides, Clostridium, 
and Bifidobacterium  (43, 45, 57), while Lactobacillus, Streptococcus, and Selenomonas  
(58) are the predominant microbes in swine. 
The administration of prebiotics has been demonstrated to stimulate growth of 
beneficial microorganism in the gastrointestinal tract (59-61). However, the selectivity 
 8 
 
of specific prebiotic compounds and the host animal species should be considered. A 
study of prebiotic administration in poultry found Lactobacillus salivarius and Lactoba-
cillus acidophilus to be the predominant lactobacilli in chickens administered fructooli-
gosaccharide (FOS), while Lactobacillus reuteri was most prevalent in chickens admin-
istered mannanoligosaccharide (MOS) (59). However, a human study found consump-
tion of fructooligosaccharide resulted in an increase of Bifidobacterium angulatum (62). 
Additionally, host-specific differences in gastrointestinal transit time may limit the effec-
tiveness of prebiotics. The effectiveness of prebiotics may be reduced in animals with 
shorter transit times due to the incomplete utilization of prebiotic substrates by gastroin-
testinal microorganisms (63). 
1.3 HOST SPECIFIC EXPERIMENTAL CONSTRAINTS 
The limitations placed on research performed in livestock in animals are different 
from those placed on research in humans. The effects of differences in these important 
experimental constraints likely contribute to perceptions of the effectiveness of probiotic 
and prebiotic application. Experimental conditions can be controlled more stringently in 
livestock animals than with human subjects. Thus, the confounding effects of uncon-
trolled or uncontrollable variables can be limited, reducing overall experimental varia-
tion and increasing experimental power. 
1.3.1 Experimental Subjects 
The nature of research subjects is an obvious factor that affects experimental de-
sign and results from probiotic and prebiotic research. Selective breeding of production 
livestock animals such as broiler chickens and Holstein cows has produced homogenous 
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in-bred genetic lines with increased uniformity and production potential (64). As a re-
sult, homogeneity between livestock animal subjects is greater than in human subjects. 
An early study evaluating oligofructose administration in humans used 8 subjects, 7 men 
and 1 woman, ranging in age from 21 to 48 (65). A meta-analysis of sixteen studies in-
vestigating the effects of probiotic and prebiotic administration on lipid levels in humans 
(66) further demonstrates the wide variations in the gender composition, age range, and 
number of subjects that can be seen in human trials. A study of probiotic reduction of di-
arrhea in weaning piglets used 256 piglets only days apart in age with an even gender 
distribution. Probiotic and prebiotic studies in chickens are able to use up to thousands of 
animals of the same age reared under identical experimental conditions (67-69). Thus, 
experimental animals are typically nearly identical in age and have far greater size, 
weight, and genetic uniformity when compared to their human counterparts. 
1.3.2 Protocol Compliance 
Strict adherence to experimental protocols is necessary for the control of varia-
bles and their influence on results. These variables are more easily maintained in live-
stock animals than with human subjects. Research animals are typically housed in facili-
ties where environmental conditions including lighting, temperature, and access to food 
and water can be controlled. However, human volunteers are not typically subjected to 
similarly rigorous constraints. The host diet is a particularly important factor that must 
be considered in studies of probiotic and prebiotic effectiveness because of its effect on 
the gastrointestinal microbiota. Replicate groups of research animals are pen fed experi-
mental rations specifically formulated for the study (23, 69), while the diet of human 
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subjects is not nearly as easily controlled. Additionally, compliance with prescribed pro-
biotic and prebiotic dose is more easily maintained for experimental animals than with 
human subjects. The removal of subjects found violating experimental protocols further 
reduces experimental power (70, 71).  
1.3.3 Ethical Considerations 
Significant interest in the potential of probiotics and prebiotics to prevent and 
treat disease has developed. The differences in ethical constraints and their effects on ex-
perimental design and study results must be considered when evaluating probiotic and 
prebiotic effectiveness (4). When evaluating the potential of probiotics and prebiotics to 
prevent infection in livestock animals, direct challenge studies in which experimental 
subjects are administered infectious to lethal doses of pathogenic microorganisms can be 
performed (72, 73). However, research in human subjects must rely on natural infection 
(32, 74) or direct challenge using attenuated pathogens (75). Alternatively, challenge ex-
periments may be performed using rodents (72, 76) as intermediate models prior to natu-
ral infection experiments in humans. 
The health of human subjects and severity of the potential infection are addi-
tional factors for consideration in natural infection studies and an additional complica-
tion over research in livestock animals. Two particularly interesting studies serve as ex-
amples highlighting the varying effectiveness of studies performed in healthy as com-
pared to ill adults. A study using healthy human volunteers performed during the com-
mon cold season found consumption of a probiotic cocktail containing Lactobacillus 
gasseri PA 16/8, Bifidobacterium longum SP 07/3, and Bifidobacterium bifidum MF 
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20/5 reduced the duration and severity of cold symptoms (77). A study evaluating the 
potential of probiotics to prevent infectious complications in patients with severe pancre-
atitis found no difference in the incidence of infectious complications (78). However, the 
number of deaths was almost 3 times greater in the probiotic treated group than in the 
placebo group. It has been reported that known complications of the experimental probi-
otic treatment were not disclosed to the study subjects (79). 
1.4 PROBIOTIC AND PREBIOTIC FUNCTIONALITY IN HUMANS AND 
LIVESTOCK 
Probiotics and prebiotics are used in order to derive a wide array of health bene-
fits for the human or livestock animal host including increased resistance to intestinal 
pathogens, improved immune health, and improved digestive function. The specific 
functionalities which provide these benefits are similar regardless of host species. How-
ever, the outcomes desired from probiotic and prebiotic use and the corresponding ex-
perimental endpoints used to measure their effectiveness are not universal across host 
species. Additionally, while improved health is the primary motivation for the use of 
probiotics and prebiotics in humans, their use in livestock animals is motivated primarily 
by the economic need for improved livestock production and performance parameters. 
1.4.1 Digestion and Metabolism 
Consumption of probiotics and prebiotics has long been known to exert positive 
effects on digestion and digestive function in humans and animals. These general bene-
fits to digestion and their contribution to nutrition and general quality of life are perhaps 
 12 
 
the most widely understood. However, their application in digestion is continuing to ex-
pand, and novel applications of this functionality are being explored. Additionally, the 
effects of probiotics and prebiotics on host animal metabolism have only recently begun 
to be understood and represent an additional novel application area in human and animal 
health.  
Probiotics have been demonstrated to improve digestibility of food, reducing 
negative effects of maldigestion while increasing the available nutrient content. Lactose 
intolerance is a common maldigestive disorder in humans. After the consumption of 
milk and dairy products, fermentation of undigested lactose by microorganisms in the 
large intestine causes discomfort to the host. The production of β-galactosidase by probi-
otic cultures in yogurt has been demonstrated to improve lactose digestion and tolerance 
(21, 80). Consumption of unfermented milk containing B. longum B6, B. longum ATCC 
15708 (81), and L. acidophilus N1 (22) have also been demonstrated to improve lactose 
digestion. Phytic acid is a phosphorus source in livestock animal feeds (82, 83) that is 
underutilized in non-ruminant livestock due to its poor digestibility (84-86). Addition-
ally, phytic acid exerts anti-nutritive effects through strong chelation of divalent cations. 
Administration of phytate-degrading Lactobacillus was demonstrated to improve weight 
gain of broiler chicks fed a phosphorous-deficient diet to a level comparable to those fed 
a phosphorus-adequate diet (Figure 1.2) (23). In addition to increasing bioavailability of 
phytate-phosphorus in monogastric livestock animals, phytate-degrading probiotic cul-
tures may be useful in correcting malabsorption syndrome in human vegetarians (87).  
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Figure 1.2. Phytate-degrading Lactobacillus improves growth of broiler chickens. 
Broiler chickens were fed a phosphorus adequate control diet (0.40% aP) and adminis-
tered a mock inoculation, or fed a phosphorus deficient diet (0.25% aP) and administered 
either a mock inoculation (MRD) or cultures of L. gallinarum TDCC 63 (rPhyA+), L. 
gallinarum TDCC 62 (Empty Vector), L. gasseri TDCC 65 (rPhyA+), or L. gasseri 
TDCC 64 (Empty Vector). Data shown are the mean body weight ± SEM of treatment 
groups. Different letters indicate means are significantly different (P < 0.05). [Adapted 
from Applied and Environmental Microbiology (Askelson et al. 2014)] with permission 
of the publisher. Copyright (2014) American Society for Microbiology)]. 
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Improved digestive function is an area that has seen significant increases in prod-
uct advertising and attention in popular press. Administration of Bifidobacterium ani-
malis DN173010 shortened intestinal transit time in women (88). Consumption of a pro-
biotic beverage containing Lactobacillus casei Shirota (89) improved gastrointestinal 
symptoms in patients with chronic constipation. Additionally, a study in children found 
treatment with Lactobacillus casei rhamnosus Lcr35 (90, 91) to have similar efficacy to 
and causing less abdominal pain than a magnesium oxide laxative.  
Results of several studies suggest probiotics and prebiotics can affect lipid me-
tabolism and potentially reduce risk factors of coronary disease in humans. Probiotics 
have been reported to reduce serum cholesterol (92). While the mechanism is not clearly 
understood, it has been hypothesized that the probiotic microorganisms may metabolize 
cholesterol and bile salts (66). In two separate studies, consumption of fermented milk 
containing L. acidophilus L1 reduced serum cholesterol (20). Similarly, serum low den-
sity lipoprotein (LDL) cholesterol was reduced by 5.4% in male volunteers who con-
sumed yogurt containing two L. acidophilus strains (DN 112.053 and DN 112.096) and 
FOS (93). 
While interest in using probiotics and prebiotics to alter lipid metabolism is not 
limited to humans, interest in livestock production is driven by production concerns. Ex-
cess fat deposition in broiler chickens is undesirable to producers because of reduced 
carcass yield and to consumers that prefer a leaner product. A probiotic mixture contain-
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ing 12 Lactobacillus strains improved body weight gain and feed conversion and re-
duced abdominal fat deposition in broiler chickens (94). Similar benefits of probiotic ad-
ministration have also been demonstrated in egg production. Pediococcus acidilactici 
MA18/5M supplementation in egg-laying hens reduced cholesterol content and in-
creased concentrations of polyunsaturated fatty acids, including linoleic acid and lino-
lenic acid, in egg yolks (95). A probiotic product containing L. acidophilus NP51 and 
Propionibacterium freudenreichii NP24 increased milk fat percentage when given to 
dairy cattle (96). While similar lipid increasing effects were seen from Bacillus subtilis 
natto in a separate study (97). Increasing, rather than decreasing milk fat percentage is 
desirable to dairy producers because of downstream processing needs.  
1.4.2 Pathogen Inhibition 
The ability of probiotics and prebiotics to reduce colonization of bacterial patho-
gens in the gastrointestinal tract is an important functionality useful for both human and 
animal health. Probiotic microbes are able to inhibit pathogens in the gastrointestinal 
tract through several mechanisms. Probiotic microorganisms competitively exclude path-
ogens from attachment to mucosal surfaces through competition for shared binding sites 
(98) and steric interference of protein adhesins located on the surface of pathogenic bac-
teria (99, 100). In addition to preventing adhesion, an in vitro study demonstrated the 
varying ability of L. acidophilus TMC 0356 and Lactobacillus rhamnosus TMC 0503 to 
displace Salmonella Typhimurium, Cronobacter sakazakii, Clostridium difficile, and 
Escherichia coli which were already adherent to human epithelial cells (29). Inhibition 
of pathogen adherence is also seen in a pig intestinal mucosa model (101). These studies 
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demonstrate probiotic strain and host specific inhibition of pathogens, highlighting need 
for case-by-case selection of probiotic cultures to reduce adherence of specific patho-
gens. 
The production of pathogen inhibiting compounds is a well understood probiotic 
mechanism (102). Neal-McKinney et al. (103) demonstrated that the production of lactic 
acid by Lactobacillus cultures to be an important mechanism for the reduction of Cam-
pylobacter jejuni in livestock animals (Figure 1.3). Hydrogen peroxide production by 
Lactobacillus has also been shown to inhibit Salmonella (104). Campylobacter (105) 
and Salmonella (106) are common inhabitants of the gastrointestinal tract of poultry and 
important human foodborne pathogens. The use of probiotics and prebiotics to reduce 
incidence of these organisms is motivated primarily by public health and food safety 
concerns rather than for the benefit of the animal. The production of bacteriocins by pro-
biotics has the potential to prevent gastrointestinal infection in humans. A direct chal-
lenge study in mice demonstrated that bacteriocin production by Lactobacillus salivarius 
UCC118 reduced counts of Listeria monocytogenes by 80 % in the liver and spleen of 
infected mice relative to a negative control (Figure 1.4) (28). Additionally, while L. sali-
varius UCC118 also protected mice from infection by Salmonella Typhimurium, the 
protection was not bacteriocin mediated. While bacteriocin production by probiotic cul-
tures is hoped to be an important alternative to antibiotics in the treatment of bacterial 
infections, the effectiveness of this mechanism has not yet been evaluated in humans. 
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Figure 1.3. Probiotic Lactobacillus cultures reduce Campylobacter jejuni coloniza-
tion of broiler chicks. Campylobacter was enumerated from the cecum of broiler chicks 
inoculated with probiotic Lactobacillus cultures or a mock inoculation and experimen-
tally challenged with C. jejuni. [Adapted from PLOS ONE (103) under the terms of the 
Creative Commons Attribution License. Copyright (2012) Neal-McKinney et al.]. 
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Figure 1.4. Lactobacillus salivarius UCC118 bacteriocin Abp118 mediates protec-
tion against Listeria monocytogenes infection. Upper, well diffusion assay. Wild type 
(wt) and Abp118 deficient (Bac-) L. salivarius UCC118 cultured in media seeded with L. 
monocytogenes and Salmonella Typhimurium. Lower, pathogens were enumerated from 
the liver of mice administered a placebo (filled bars), wild-type L. salivarius UCC118 
(open bars), or Bacteriocin deficient (Bac-) L. salivarius UCC118 (gray bars) and in-
fected with L. monocytogenes EGDe, L. monocytogenes LO28, or Salmonella Typhi-
murium. Different letters indicate means differ significantly (P < 0.001; n = 5). [Re-
printed from the Proceedings of the National Academy of Sciences of the United States 
of America (28) with permission of the publisher. Copyright (2007) National Academy 
of Sciences, U.S.A.]. 
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1.4.3 Immune Modulation  
Significant interest has grown in the immune modulating effects of probiotics 
and prebiotics. Probiotics are able to directly stimulate immune responses and regulate 
inflammation in a strain specific manner. While prebiotic immunomodulation is thought 
to occur primarily in collaboration with commensal microorganisms (33), there is evi-
dence suggesting that carbohydrate polymers can directly interact with cells of the im-
mune system (107). 
In addition to the direct action against pathogens described previously in this 
work, probiotics have been demonstrated to help protect the host from pathogens by en-
hancing host defenses. The probiotic cocktail VSL #3 improved epithelial barrier func-
tion and prevented Salmonella invasion of epithelial cells (108), while L. casei 
CHCC3139 stimulated the production of cytokines responsible for cell-mediated immun-
ity (109, 110). A synbiotc combination of a commercial direct fed microbial (Milkibeef 
Top, Trouw Nutrition) containing Enterococcus faecium and prebiotic lactulose in-
creased mRNA expression of IgA Fc receptor when administered to calves (34). Human 
infants fed formula containing FOS or galactooligosaccharide (GOS) had greater fecal 
secretory IgA than infants fed control formula (111). 
Probiotic cultures including Lactobacillus species (112, 113) and prebiotics in-
cluding mannanoligosaccharide (114) have been demonstrated to reduce expression of 
inflammatory cytokines. Management of inflammatory bowel disorders (115) and atopic 
allergy are areas where the anti-inflammatory effects of probiotics and prebiotics show 
promise. Several studies demonstrate the potential of probiotic bacteria (116, 117) and 
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yeast (118) to induce remission of active ulcerative colitis. Atopic diseases including 
atopic eczema, allergic asthma, and allergic rhinitis are allergic hypersensitivities. Im-
munomodulatory probiotics may be useful in preventing or reducing the severity of 
atopic disease (31). One double blind placebo controlled study observed diminished clin-
ical signs and symptoms of atopy in infants receiving L. rhamnosus GG and Bifidobacte-
rium lactis BB-12 (119). Oral bacteriotherapy with L. rhamnosus 19070-2 and L. reuteri 
DSM 122460 reduced proinflammatory eosinophil cationic protein in older children with 
atopic dermatitis (13). While probiotics and prebiotics may exhibit anti-inflammatory 
properties in livestock animals, management of chronic intestinal inflammation and 
atopic disease is likely to be more applicable in humans than in livestock.  
1.5 FUTURE PERSPECTIVES 
1.5.1 Diarrheal Disease 
The morbidity and mortality in humans (120, 121) and losses to livestock pro-
duction (122, 123) due to bacterial and viral enteric disease is significant, making the re-
duction of diarrheal disease in humans and livestock an important global health objec-
tive. The combined pathogen inhibiting and immune stimulating functionality of probiot-
ics and prebiotics suggests they may be able to contribute to achieving this important 
goal. Nosocomial infectious diarrhea is an important problem in children, prolonging 
hospital stays and increasing medical costs (124). Several studies have demonstrated the 
ability of probiotic L. rhamnosus GG to reduce the incidence of diarrhea in children (32, 
125). Additionally, the efficacy of several probiotics in preventing antibiotic-associated 
diarrhea (126) and Traveler’s Diarrhea (127) has also been shown. Similar reduction of 
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diarrhea in swine and cattle have also been demonstrated (128). Administration of probi-
otic Bacillus cultures reduced post-weaning diarrhea syndrome related mortality (12) in 
piglets. Additional studies have shown probiotic-mediated reduction of diarrhea and 
complications from pathogenic E. coli in piglets (129, 130) similar to L. rhamnosus GG 
in infants. 
1.5.2 Agricultural Sustainability 
Rapid growth in the use of renewable biofuels has led to a reallocation of arable 
land from food to fuel ethanol production (131) and forced livestock producers to be-
coming increasingly reliant upon secondary feedstocks that are poorly digested with 
lower available nutrient content. The ability of probiotics to increase digestibility and 
nutrient utilization from poorly digested feed constituents through biocatalysis (23) in 
the gastrointestinal tract will become important as feed costs continue to increase. Addi-
tionally, the immune stimulating functionality of probiotics and prebiotics will continue 
to be important in disease management and potentially reduce losses in livestock produc-
tion (132-134). Thus, by increasing efficiency and overall productivity, probiotics and 
prebiotics have the potential to make important contributions to agricultural sustainabil-
ity and global nutritional security. 
1.5.3 AGP Alternatives 
AGPs have been widely used to increase weight gain (135), improve feed effi-
ciency (136, 137), and reduce mortality in livestock animal production (138, 139). Regu-
latory and consumer concerns over the development of antibiotic resistant microbes have 
led to a decline in the non-therapeutic use of antibiotics (140). However, the reduction of 
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their use has led to reduced livestock productivity and increased disease in production 
animals. Supplementation of livestock feed with probiotics and prebiotics has been 
demonstrated to improve growth performance to levels similar to antibiotics, thus they 
represent an important alternative to the use of AGPs in livestock production (15). How-
ever, while the use of probiotic cultures with growth promoting properties are desirable 
in livestock animal production, their use in humans is undesirable due to the growing 
worldwide obesity epidemic.  
1.5.4 Vaccine and Anti-infective Delivery  
Because of their long history of safe use, immune stimulating functionality, and 
importance in human and animal health, probiotic microorganisms have received consid-
erable interest as potential vectors for the delivery of vaccines antigens to mucosal sur-
faces (141). An increasing number of studies have investigated the potential of live pro-
biotic microorganisms as vaccines with several of examples in which they have elicited 
antigen specific immune responses (Table 1.3). Additionally, “bioshield” strategies in 
which probiotic microorganisms confer passive immunity through expression of receptor 
proteins or antibody fragments are also being explored (141). The use of recombinant 
probiotic cultures for this novel functionality is expected to be widely applicable in both 
human and animal health and for improving food safety as well. 
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Table 1.3. Examples of vaccines delivered by probiotic microorganisms 
Organism Antigen Host References 
Lactobacillus acidophilus 
NCFM 
B. anthracis PA 
Mouse (142) 
 HIV-1 Gag  Mouse (143) 
Lactobacillus casei ATCC 393 CSFV epitope 290 
Parvovirus VP2 
Pig (144) 
Lactobacillus plantarum 
NCIMB8826 
Dust mite allergy Derp p 1 
Mouse (145) 
 C. tetani TTFC Mouse (146) 
Lactococcus lactis E7 
Lactococcus lactis IL-12 
HPV E7 
Mouse (147). 
Lactococcus lactis NZ9000 Avian influenza HA Chicken (148) 
Pichia pastoris SMD1168 CSFV glycoprotein E2 Pig (149) (150) 
Pichia pastoris KM71H C. perfringens α toxin Chicken (46) 
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2. TARGETED GENE INACTIVATION IN LACTOBACILLUS GALLINARUM 
ATCC 33199 USING CHROMOSOMAL INTEGRATION 
 
2.1 INTRODUCTION 
Lactobacillus species are important inhabitants of the gastrointestinal tracts of 
humans and livestock animals and are often used as probiotics because of their health 
promoting properties (151). Probiotics are live microorganisms, which when adminis-
tered in adequate amounts confer a health benefit on the host (152). Often administered 
as Direct-Fed Microorganisms to poultry and other livestock animals, probiotic Lactoba-
cillus have been demonstrated to stimulate immune responses (153, 154), reduce coloni-
zation of human food-borne pathogens including Campylobacter (155) and Salmonella 
(73), and improve growth performance at levels similar to antibiotics (156, 157). Addi-
tionally, interest in the use of probiotics in livestock animal production has grown be-
cause of increased consumer and regulatory pressure to reduce sub-therapeutic use of an-
tibiotics (158). Although they are used widely in livestock animal production, the mech-
anisms responsible for the benefits of probiotic administration are not well understood.  
Lactobacillus gallinarum ATCC 33199, originally isolated from the crop of a 
chicken, is a potentially important model organism for investigating mechanisms of pro-
biotic functionality in poultry. L. gallinarum ATCC 33199 has been demonstrated to ad-
here effectively to the chicken LMH epithelial cell line in vitro and to be a strong colo-
nizer of the gastrointestinal tract of broiler chickens in vivo (159). Administration of L. 
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gallinarum ATCC 33199 has been also demonstrated to reduce colonization by Campyl-
obacter jejuni in experimentally challenged broiler chickens (160). Recently, the ge-
nome sequence for L. gallinarum ATCC 33199 (161) has been made available and is ex-
pected to provide genomic insights into the beneficial functionalities of Lactobacillus in 
the gastrointestinal tract of poultry. Additionally, the ability to be genetically trans-
formed readily using electroporation and recombinant expression of heterologous pro-
teins has been demonstrated in L. gallinarum ATCC 33199 (23). Although the genetic 
tractability of this organism has been demonstrated, the ability to construct targeted iso-
genic mutants will also be required to investigate the role of specific genes and gene 
products in the probiotic functionality of this organism. 
The pORI28-plasmid system, based on the broad-host-range lactococcal pWV01 
replicon (162), has been used widely for the targeted insertional inactivation of genes in 
Lactic Acid Bacteria (LAB). Targeted gene inactivation using pORI28-based plasmids is 
dependent upon the integration of a non-replicating plasmid containing an antibiotic re-
sistance cassette into the host chromosome by homologous recombination. This has been 
demonstrated to be an efficient method for the construction of isogenic gene knockout 
mutants in several Lactobacillus species and has provided important insight into carbo-
hydrate metabolism (163, 164), epithelial cell adhesion (165), and bile stress response of 
Lactobacillus species (166, 167). In this study, we investigated insertional inactivation 
of lacL, encoding β-galactosidase, in order to demonstrate proof-of-principle of the ef-
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fectiveness of the pORI28 system in L. gallinarum ATCC 33199 and to provide a plat-
form to enable functional genomic analyses investigating mechanisms of probiotic func-
tionality in the gastrointestinal tract of poultry using this organism. 
2.2. MATERIALS AND METHODS 
2.2.1 Bacterial Strains, Plasmids, and Growth Conditions 
Bacterial strains and plasmids used in this study are listed in (Table 2.1). Lacto-
bacillus gallinarum strains were cultured in 10% CO2 at 37°C using de Man, Rogosa, 
and Sharpe (MRS) (Becton Dickinson, BD, Franklin Lakes, New Jersey) medium sup-
plemented with 5 μg mL-1 erythromycin (Erm) (EMD Chemicals, Inc., San Diego, CA) 
or 5 μg mL-1 chloramphenicol (Cam) (EMD) when appropriate. Escherichia coli strains 
were cultured at 37°C using Luria-Bertani (LB) broth (Becton Dickinson) and Brain 
Heart Infusion (BHI) agar (Becton Dickinson) supplemented with 100 μg mL-1 ampicil-
lin (Amp) (Fisher BioReagents, Waltham, MA), 150 μg mL-1 Erm, or 150 μg mL-1 kana-
mycin (Kan) (Fisher) when appropriate. 
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Table 2.1. Bacterial strains and plasmids used in this study 
Strain or plasmid Relevant characteristics Source or reference 
Lactobacillus gallinarum 
ATCC 33199T Type strain, chicken crop isolate ATCC1 
TDCC 97 ATCC 33199 w/ pTRK669 This study 
TDCC 98 ATCC 33199 w/ lacL::pTD017 insertion, LacL- This study 
Escherichia coli  
EC1000 RepA+, Km
r, replication host for pORI28- based 
plasmids, chromosomal insertion of repA in glgB 
(168) 
TDCC 96 EC1000 w/ pTD017 This study 
Plasmids  
pCR2.1 3.9 kb, Ori (pUC19), Amr intermediate TOPO-TA 
cloning vector 
Invitrogen 
pORI28 1.7 kb, Ori (pWV01), Emr, Rep-, replicates only 
with repA  provided in trans, integration vector 
(169) 
pTRK669 2.9 kb, Ori (pWV01), Cmr ,Repts, provides repA in 
trans  
(170) 
pTD016 4.6 kb pCR2.1 w/ 651-bp internal L. gallinarum 
lacL fragment  
This study 
pTD017 2.4 kb pORI28 w/ 651-bp internal L. gallinarum 
lacL fragment 
This study 
1 American Type Culture Collection 
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2.2.2 DNA Isolation, Manipulations, and Transformations 
E. coli plasmid DNA was isolated using the QIAprep Spin Miniprep kit (Qiagen 
Inc., Valencia, CA), whereas genomic DNA was isolated from Lactobacillus using the 
method of Walker and Klaenhammer (171). All DNA manipulations were performed us-
ing standard molecular cloning techniques (172). Restriction endonucleases, T4 Ligase, 
Antarctic phosphatase, and Taq DNA polymerase were used according to the manufac-
turer’s instructions (New England Biolabs, Ipswich, MA). PCR Primers were designed 
using Clone Manager (Scientific and Educational Software, Cary, NC) and commer-
cially synthesized (Integrated DNA Technologies, Coralville, IA). PCR products and re-
striction fragments were purified using the QIAquick PCR purification and gel extrac-
tion kits (Qiagen), respectively. 
Electrocompetent E. coli TOP10 and EC1000 were prepared and transformed ac-
cording to manufacturer's directions and standard methods (173), respectively. Electro-
competent Lactobacillus gallinarum was prepared using 3.5 × Sucrose MgCl Electro-
poration Buffer (SMEB) and electrotransformed as described by J. B. Luchansky et al. 
(174) using a GenePulse Xcell electorporator (Bio-Rad, Hercules, CA). 
2.2.3 Gene Inactivation 
The inactivation of lacL was performed using targeted insertion of an erythromy-
cin resistance cassette by homologous recombination using methods adapted from W. M. 
Russell and T. R. Klaenhammer (170). A 651-bp internal fragment of L. gallinarum 
ATCC 33199 lacL (Accession PRJDB621) was PCR amplified using chromosomal tem-
plate DNA and primers LGlacL_F (5’ - CGGGCCATGTATGTCTATCTC - 3’) and 
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LGlacL_R (5’ – TTGCTTCATGTCGGCTAGG - 3’). Purified PCR product was ligated 
into pCR2.1-TOPO-TA and subsequently subcloned via NotI and HindIII restriction 
sites into pORI28. The resulting plasmid, pTD016 (pORI28::lacL) was transformed into 
L. gallinarum TDCC 96 harboring pTRK669. Selection for chromosomal integration of 
pTD016 in lacL was performed at 42°C, a temperature non-permissive to pTRK669, in 
MRS broth with Erm selection. Presumptive lacL integration mutants were identified us-
ing blue/white selection on MRS agar supplemented with Erm, 20μg mL-1 IPTG (RPI, 
Corp., Mount Prospect, IL) and 50μg mL-1 X-gal (AMRESCO LLC, Solon, OH) 
2.2.4 Southern Hybridization 
HindIII-digested chromosomal DNA was separated using agarose gel electropho-
resis, transferred onto a positively charged nylon membrane (Roche Diagnostics, Basel, 
Switzerland) and UV cross-linked (Stratalinker, Stratagene, La Jolla, CA). DIG-labled 
DNA molecular weight marker was included as a control (Roche). The membrane was 
blocked, probed using DIG-labled 651 bp lacL PCR product, and visualized using anti-
DIG conjugated alkaline phosphatase and p-nitrophenyl phosphate using the Dig Easy 
Hyb system (Roche) according to the manufacturer’s instructions.  
2.2.5 Growth Analysis 
Wild Type and lacL- Lactobacillus gallinarum strains were cultured overnight 
using MRS medium and harvested by centrifugation (5,000  g, 10 min, 4°C). Cells 
were washed and  resuspended in carbohydrate-free Menon-Sturino (MS) medium (175) 
and inoculated at 1% (v/v) into MS broth supplemented with either 100 mM fructose 
(Sigma-Aldrich, St. Louis, MO), 100mM glucose (Sigma-Aldrich), 50 mM sucrose (J. 
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T.Baker, Center Valley, PA), and 50 mM lactose (Sigma-Aldrich). Growth of cultures at 
37°C was monitored by absorbance (O.D.600 nm) using a microplate reader (Tecan, Mor-
risville, NC). 
2.2.6 Stability of Integrated Plasmid 
Stability of integrated pTD016 in the chromosome of L. gallinarum was deter-
mined by propagating L. gallinarum TDCC 98 in MRS broth in the absence of antibiotic 
selection for 50 generations as described in W. M. Russell and T. R. Klaenhammer 
(170). After every 10 generations of propagation L. gallinarum was plated on MRS agar 
with X-Gal and IPTG and incubated for 48 hours. Revertant colonies were indicated by 
the ability to hydrolyze X-gal. 
2.3 RESULTS 
2.3.1 Insertional Inactivation of lacL 
The lacL gene, putatively encoding β-galactosidase, was identified using the 
draft genome sequence of L. gallinarum ATCC 33199 (161). Presumptive integrants 
were selected from Erm-resistant L. gallinarum pTD016 transformants which formed 
white colonies on plates supplemented with X-gal and IPTG indicating disruption of β-
galactosidase activity.  
2.3.2 Southern Hybridization Confirms Plasmid Insertion 
Disruption of the lacL gene by chromosomal integration of pTD016 was con-
firmed using Southern hybridization (Figure 2.1) and PCR (not shown). For the WT 
strain (Lane 1), the lacL probe hybridized to a band corresponding to the 5.7 kb HindIII 
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restriction fragment predicted from the L. gallinarum genome sequence. For the lacL in-
tegrant (Lane 2), the probe hybridized to two bands of approximately 6.6 kb and 1.5 kb, 
indicating insertion of an additional HindIII restriction site into the lacL locus by the in-
tegration of the plasmid. An additional restriction fragment similar in size to the pTD016 
control (Lane 3) indicated amplification of the inserted plasmid within the lacL locus.  
2.3.3 Growth Curves 
The ability of the lacL mutant (L. gallinarum TDCC 98) to grow on various car-
bohydrates was evaluated (Figure 2.2). Cultures of wild type L. gallinarum were able to 
grow effectively in all four carbohydrates. Cultures of the L. gallinarum lacL integrant 
were able to grow in fructose, glucose, and sucrose, reaching a similar final O.D.600 as 
the wild type cultures. However, lacL integrant cultures were not able to grow in lactose 
indicating disruption of β -galactosidase activity due to integration of pTD016 in the 
lacL locus of L. gallinarum.  
2.3.4 Stability of lacL Integrants 
Loss of the integrated plasmid was assessed by the restoration of β-galactosidase 
activity, indicated by the appearance of blue colonies (Figure 2.3). The number of re-
vertant colonies was evaluated every 10 generations over a total 50 generations. The per-
centage of revertants gradually increased over the first 40 generations but did not con-
tinue to increase from 40 to 50 generations. The maximum percentage of revertants 
reached a maximum of 1.67% after 50 generations, at a rate of 0.03% per generation 
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Figure 2.1. Southern hybridization analysis confirms chromosomal integration of 
pTD016 in lacL. (A) L. gallinarum ATCC 33199 (Lane 1), L. gallinarum TDCC 98 
(Lane 2), and pTD016 (Lane 3). DNA was digested using HindIII and probed with DIG-
labeled 651-bp lacL internal fragment. M, DIG-labeled DNA Molecular Weight Marker 
II. (B) Schematic of lacL locus of L. gallinarum ATCC 33199 (WT) and L. gallinarum 
TDCC 98 (lacL-). Chromosomal DNA is represented by solid line, plasmid DNA is rep-
resented by dotted line, the lacL gene is represented by an arrow, and internal lacL frag-
ment is represented by shaded box. HindIII (H) restriction sites and predicted length of 
restriction fragments is indicated. 
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Figure 2.2. Chromosomal integration in lacL abolishes growth on lactose. Cultures 
of (A) WT and (B) lacL- L. gallinarum strains were cultured in MS broth supplemented 
with 100 mM Fructose (), 100 mM glucose (), 50 mM sucrose (), and 50 mM lac-
tose (□). Cell density is indicated as the mean ± SEM absorbance (O.D.600 nm) of four in-
dependent cultures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Stability of pTD016 insertion in L. gallinarum lacL. Reversion rate calcu-
lated as the percentage of revertant colonies appearing on MRS agar supplemented with   
50μg mL-1 X-Gal and 20μg mL-1 IPTG. 
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2.4 DISCUSSION 
The objective of this study was to adapt the pORI28 chromosomal integration 
system for use in Lactobacillus gallinarum ATCC 33199 and demonstrate proof-of-prin-
ciple of its functionality in this strain by constructing a targeted gene insertion mutant of 
lacL. Administration of probiotic Lactobacillus has been demonstrated to promote 
growth at levels similar to antibiotics (157, 176) and reduce colonization of pathogens in 
the gastrointestinal tract in poultry (73, 155, 177). Lactobacillus strains isolated from 
chickens have often been reported to be recalcitrant to transformation (178). We have 
previously demonstrated the ability of L. gallinarum ATCC 33199 to be transformed 
readily with the pWV01 replicon by electroporation (23) and to effectively colonize the 
gastrointestinal tract of poultry (159). Additionally, the genome sequence of this poultry 
isolate has been made available (161), suggesting this strain as a potentially important 
model organism for investigating probiotic functionality in poultry.  
The pORI28-plasmid system (169), based on the broad-host-range lactococcal 
pWV01 replicon (162), has been used widely for the targeted insertional inactivation of 
genes in Lactic Acid Bacteria (LAB)(170, 179). Derivatives of pWV01, including 
pGK12 (180), have been demonstrated to be efficiently replicated while maintaining a 
high copy number in both Gram-negative (180) and Gram-positive (181) microorgan-
isms, including Borrelia burgdorferi (182) and Listeria monocytogenes (183). Targeted 
chromosomal insertion has been used widely in the construction of isogenic loss-of func-
tion mutants necessary to investigate physiology and metabolism of Lactobacillus (170, 
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184, 185) and other microorganisms. Although the CRISPR/Cas system has recently be-
come a preferred technology for gene editing (186), the native CRISPR/Cas systems en-
coded in the genome of the bacterium of interest is often used. However, CRISPR/Cas 
elements have not been not detected in the genome sequence of L. gallinarum ATCC 
33199 (161). Additionally, targeted chromosomal insertion of pORI28 derivatives will 
facilitate detection of L. gallinarum knock-out mutants during in vivo studies in poultry, 
with erythromycin resistance used as a selective marker and non-native sequences of the 
plasmid used as targets for molecular detection methods.  
β-galactosidase has been used widely as a reporter in genetic studies to because 
of the easily observed phenotype (187-190). Targeted insertion of pTD016 into the lacL 
locus of L. gallinarum disrupted β-galactosidase activity and abolished growth on lac-
tose. Growth of the lacL integrant cultures on the other carbohydrates was similar to the 
wild-type cultures, confirming their fermentation was not affected by inactivation of 
lacL. Similar results have been observed for β-galactosidase knock-out mutants con-
structed in other LAB (170, 191). Additionally, a lag period was observed for cultures of 
the lacL mutant compared to the wild-type when cultured in fructose, glucose, and su-
crose, and has been observed previously when pORI28-based mutants were cultured un-
der antibiotic selection (163). The inability of the mutant to grow in lactose suggests 
lacL encodes the only β-galactosidase in the genome of L. gallinarum ATCC 33199 and 
is consistent with predictions from the genome sequence for this organism (161).  
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Southern hybridization analysis confirmed disruption of β-galactosidase was due 
to integration of the pTD016 in the lacL locus of L. gallinarum. Presence of an addi-
tional band of approximately similar size to the inserted plasmid indicated amplification 
of the insert within the lacL locus. Similar amplification has been reported previously for 
plasmid insertions maintained under antibiotic selection in other microorganisms (162, 
163, 170). 
The observed total reversion of less than 2% in the absence of antibiotic selection 
is similar to the stability of chromosomal integrations after 50 generations reported pre-
viously for other Lactobacillus (170, 192) and is significantly greater than has been re-
ported for gene knockout systems in other bacteria (193-195). L. gallinarum ATCC 
33199 has been demonstrated to colonize chickens only transiently with its recovery de-
creasing significantly 4 days post-inoculation (159), suggesting that pORI28-based 
knock-out mutants will be sufficiently stable for application during in vivo studies in 
broiler chickens. 
In this study, we constructed a knock-out mutant of lacL using insertional inacti-
vation in order to demonstrate proof-of-principle of the effectiveness of the pORI28 sys-
tem in L. gallinarum ATCC 33199. We have successfully demonstrated that integration 
of pTD016 (pORI28::lacL) into the lacL locus of disrupted β-galactosidase activity and 
abolished the ability of integrant to utilize lactose without affecting growth on other car-
bohydrates. To the best of our knowledge, this is the first report of targeted gene inacti-
vation in a Lactobacillus culture isolated from poultry. The application of the pORI28 
system will allow the construction of additional isogenic mutants to be used to support 
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investigation of mechanisms important to the beneficial functionality of probiotic micro-
organisms in poultry.  
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3. EFFECTS OF DIRECT-FED MICROORGANISMS AND ENZYME BLEND  
CO-ADMINISTRATION ON INTESTINAL BACTERIA IN BROILERS FED 
 DIETS WITH OR WITHOUT ANTIBIOTIC2 
 
3.1 INTRODUCTION 
Sub-therapeutic doses of antibiotics have been used to promote the growth of 
broiler chickens in the United States for more than 50 years (135, 196, 197).Antibiotic 
growth promoters (AGP) have been demonstrated to increase weight gain (135), im-
prove feed efficiency (136, 137), and reduce mortality in livestock animals (139, 198). 
However, the use of AGPs has declined (140) because of increased concerns regarding 
the development of antibiotic resistant bacteria (199), and their use has been banned in 
the European Union (200) and limited in the United States by the Veterinary Feed Di-
rective (201). Because of growing interest in low-input and antibiotic free (ABF) pro-
duction practices, the development of effective alternatives to the sub-therapeutic use of 
antibiotics is of significant interest to animal agriculture. 
The growth-promoting activity of antibiotics is attributed to their effect on the 
gastrointestinal microbiota (199) and are not observed when administered to germ-free 
animals (202). However, increased growth is observed when antibiotics are administered 
to animals with normal microbiota (135, 203, 204). Additionally, growth is depressed 
                                                 
2 Reprinted with permission from “Effects of direct-fed microorganisms and enzyme blend co-administra-
tion on intestinal bacteria in broilers fed diets with or without antibiotics.” Askelson, T. E., C. A. Flores, S. 
L. Dunn-Horrocks, Y. Dersjant-Li, K. Gibbs, A. Awati, J. T. Lee, and T. Duong. 2017. Poultry Science. 
pex270. doi 10.3382/ps/pex270 
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when germ-free animals are inoculated with normal microbiota (205), suggesting intesti-
nal microorganisms are competitive with growth performance of the host animal (136). 
Modification of the host microbiota by antibiotics has been suggested to improve growth 
performance of livestock through inhibition of subclinical infections (206), reduced 
competition for nutrients between the microbiota and host-animal (207, 208), decreased 
production of growth depressing metabolites by the resident microbiota (209), and en-
hanced absorption of nutrients through the thinner intestinal wall of antibiotic-fed ani-
mals (210, 211).  
Administration of probiotics, sometimes called Direct-Fed Microorganisms 
(DFM) when used in livestock animals (212), has been demonstrated to improve growth 
performance at levels similar to AGPs (16, 156). Additionally, they have been demon-
strated to improve pre-harvest food safety of poultry by reducing colonization of human 
food-borne pathogens including Salmonella (73, 213) and Campylobacter (30, 214) in 
the gastrointestinal tract; improve poultry health by reducing colonization by poultry 
pathogens including Clostridium perfringens (215, 216) and avian pathogenic Esche-
richia coli (217); and reduce inflammation induced during C. perfringens associated ne-
crotic enteritis (218). 
Cereal grains commonly used in livestock animal feed contain anti-nutrients in-
cluding non-starch polysaccharides (NSP), resistant starches, and indigestible proteins 
which are poorly digested by monogastric animals (219, 220). Additionally, NSPs exert 
anti-nutritive effects through chelation of important metal cations including calcium, 
iron, and magnesium (221), reduce nutrient absorption by increasing the ileal  viscosity 
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(222), and alter the gastrointestinal microbiota (223). Digestive enzymes including xy-
lanases, amylases, and proteases are used routinely in animal feeds to improve digestibil-
ity (224, 225) and reduce anti-nutritive effects of poorly digested feed constituents (226, 
227); and their effect on growth performance has been well demonstrated (228-230). Ad-
ditionally, the products of the hydrolysis of indigestible feed constituents by exogenous 
feed-additive enzymes may produce substrates that promote the growth or activities of 
beneficial bacteria (231), which suggests the administration of particular enzyme blends 
may confer an additive benefit when combined with appropriate Direct-Fed Microorgan-
isms. This potential prebiotic-like effect on growth performance suggests the co-admin-
istration of enzyme blends with DFM may be an important component of ABF manage-
ment programs. 
The co-administration of DFMs with feed-additive enzymes has been investi-
gated previously. In addition to improving growth performance, co-administration of 
Lactobacillus plantarum and xylanase was demonstrated to reduce fecal shedding of Sal-
monella Typhimurium in experimentally challenged broilers (232). Administration of a 
multi-strain DFM product containing Bifidobacterium animalis and several Lactic Acid 
Bacteria (LAB) in combination with xylanase improved growth performance when com-
pared to either product individually (233). Dersjant-Li et al. (234) demonstrated previ-
ously that administration of a multi-strain Bacillus amyloliquefaciens DFM product in 
combination with an enzyme complex composed of xylanase, amylase, and protease 
(XAP) improved growth performance in broilers fed a diet with reduced energy and di-
gestible amino acids. Although the use of antibiotics in poultry production is continuing 
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to decline, the use of antibiotics non-medically relevant, including BMD and Vir-
giniamycin has not been prohibited, and the effect of antibiotics on the efficacy of DFM 
and DFM containing products is not well understood. In this study, we evaluated the ef-
fect of a feed additive containing three strains of B. amyloliquefaciens and XAP de-
scribed previously, administered with or without AGP on the gastrointestinal microbiota 
and growth performance of broiler chickens. 
3.2 MATERIALS AND METHODS 
3.2.1 Experimental Design 
Male broilers (Cobb 500, n = 2160) were obtained from a commercial hatchery 
on day of hatch, randomly assigned to treatment pens with similar starting weights, and 
provided experimental feed and water ad libitum for the duration of the study. Experi-
mental animals were allocated to 6 experimental treatment groups with 9 replicate pens 
of 40 broiler chicks arranged as a randomized complete block design. Experimental 
treatment groups were fed experimental rations which contained combinations of an 
AGP [control (-AGP), bacitracin methylene disalicylate (BMD), or virginiamycin 
(VM)] and a feed additive (ADD3) composed of a DFM culture containing spores of 
three Bacillus amyloliquefaciens strains (7.5  10 7 cfu kg-1 feed) and an enzyme blend 
Trichoderma reesei endo-xylanase (2000 U kg-1 feed), Bacillus licheniformis α-amylase 
(200 U kg-1 feed), and Bacillus subtilis serine protease (4000 U kg-1 feed) (XAP) (Table 
3.1). All animal care and experimental procedures were performed in accordance with 
protocols approved by the Texas A&M University Institutional Animal Care and Use 
                                                 
3 (DFM + XAP, Syncra AVI, Danisco Animal Nutrition/DuPont, Marlborough, Wiltshire, UK) 
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Committee. Additional details including experimental design, experimental diets, animal 
husbandry, and growth performance measures are presented in a separate publication 
(235) 
3.2.2 Bacterial Enumeration   
At 21 and 42 days post-hatch, a single chicken of approximately mean pen 
weight (± 5%) was selected from each replicate pen, euthanized, and necropsied for the 
collection of tissues for the enumeration of gastrointestinal microorganisms. The ceca 
and a section (~ 6 cm) of the ileum centered on the midpoint between Meckel’s divertic-
ulum and the ileocecal junction were dissected aseptically from each selected chicken. 
Ileal specimens were homogenized and diluted using Fluid Thioglycolate Medium 
(FTM; BD, Franklin Lakes, NJ), whereas cecal specimens were homogenized and di-
luted using sterile phosphate buffered saline (PBS; Fisher Scientific, Pittsburgh, PA). 
Campylobacter jejuni, Escherichia coli, Salmonella, and total Lactic Acid Bacteria 
(LAB) were enumerated from the ceca using Campy Cefex agar (Hardy Diagnostics, 
Santa Maria, California), Compact Dry EC plates (EC; Hardy Diagnostics), Xylose-Ly-
sine-Tergitol-4 agar (XLT-4; BD), and deMan, Rogosa, and Sharpe agar (MRS; BD) 
supplemented with 100 µg∙mL−1 cycloheximide (Amresco, Solon, OH), respectively. 
Clostridium perfringens was enumerated from the ileum using Tryptose Sulphite Cyclo-
serine Egg Yolk overlay agar (TSC-EY; BD). EC and XLT-4 were incubated aerobi-
cally at 37 oC for 36 h. Campy Cefex and MRS were incubated in 10% CO2 at 42 
oC and  
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Table 3.1. Feed Conversion of Broiler Chickens 
Treatment  FCR (Feed:Gain) 
AGP ADD1  D 0-21 D 22-42 D 0-42 
- -  1.380a 1.875a 1.663a 
- +  1.358bc 1.830b 1.625b 
BMD2 -  1.357bc 1.824b 1.625b 
BMD +  1.356bc 1.807b 1.612b 
VM3 -  1.371ab 1.831b 1.636ab 
VM +  1.352c 1.806b 1.612b 
One-way P -values  0.007 0.018 0.003 
      
Main Effects     
AGP     
Control  1.369 1.849a 1.644a 
BMD  1.357 1.818b 1.619b 
Virginiamycin  1.362 1.816b 1.624b 
Feed Additive     
Control  1.369a 1.842a 1.641a 
ADD  1.356b 1.813b 1.616b 
P -values     
AGP  0.079 0.016 0.015 
Feed Additive  0.002 0.005 <0.001 
AGP×Feed Additive  0.092 0.492 0.332 
Pooled SEM  0.002 0.007 0.004 
a - c different superscripts within columns indicate means are significantly 
different  (P ≤ 0.05) 
1DFM + XAP; 2Bacitracin Methylene Dialicylate (50 g t-1) 
3Virginiamycin (20 g t-1)  
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37oC, respectively, for 36 h. TSC-EY was incubated at 37 oC anaerobically (Coy 
Laboratory Products, Grass Lake, MI) for 36 h. C. jejuni was selectively enriched from 
cecal specimens using Bolton’s Enrichment Broth (BEB, Hardy Diagnostic) incubated at 
42 oC for 24 h followed by Campy Cefex agar. Salmonella was from cecal specimens us-
ing Rappaport Vassiliadis R10 broth (RV; BD) incubated at 42oC for 24 h and XLT-4 
agar. 
C. perfringens was selectively enriched from the ileum using FTM incubated an-
aerobically at 37°C for 24 h followed by Iron Milk Medium incubated at 46oC for 3 h. 
Specimens for which there were no colonies appearing on enumeration plates but were 
positive by selective enrichment were assigned the lower limit of detection, 100 cfu g-1 
for statistical analysis. 
Presumptive C. perfringens were confirmed using Iron Milk Medium, whereas 
presumptive C. jejuni, E. coli, and Salmonella colonies were confirmed by PCR using 
species-specific primers (Table 3.2). C. jejuni ATCC 29428, E. coli ATCC 25922, and 
Salmonella Typhimurium ATCC 14028 were used as positive controls for PCR 
 
 
 
Table 3.2. PCR primers used in this study 
Species Gene Primer Sequence (5’-3’) Reference 
C. jejuni cadF cadF-F2B TTG AAG GTA ATT TAG ATA TG (236) 
  cadF-R1B CTA ATA CCT AAA GTT GAA AC  
E. coli tuf TEcol553 TGG GAA GCG AAA ATC CTG (237) 
  TEcol754 CAG TAC AGG TAG ACT TCT G  
Salmonella invA INVA-1 ACA GTG CTC GTT TAC GAC CTG AAT (238) 
  INVA-2 AGA CGA CTG GTA CTG ATC GAT AAT  
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3.2.3 Statistical Analysis 
Bacterial counts were log10 transformed for analysis and reported as the mean ± 
SEM log10 cfu g
-1 digestive contents from 9 replicate pens per treatment. Data were ana-
lyzed using factorial ANOVA with main effects for AGP, Feed Additive, and AGP 
Feed Additive. A one-way ANOVA was used to determine differences between indi-
vidual treatment groups. Significantly different means (P ≤ 0.05) were separated using 
Duncan’s multiple range test. Associations between bacterial counts and feed conversion  
ratio (FCR) were evaluated by pens using Pearson’s r. Analyses were conducted with 
IBM SPSS Statistics (V. 24.0, IBM Corp., Armonk, NY). 
3.3 RESULTS 
3.3.1 Gastrointestinal Microbiota 
3.3.1.1 Gram-positive Bacteria. Recovery of total Lactic Acid Bacteria (LAB) 
was greater from broilers treated with virginiamycin (VM) and the feed additive (ADD) 
in combination than from the remaining treatment groups on Day 21 and Day 42 (Figure 
3.1 A-B). On Day 21, recovery of Clostridium perfringens was greater from untreated 
broilers than from the remaining treatment groups (Figure 3.1 C), whereas, on Day 42, 
recovery of C. perfringens was greatest from broilers administered VM alone (Figure 
3.1 D). Administration of ADD increased counts of total LAB in the cecum of broiler 
chicks on Day 21 (P = 0.028) but had no effect on Day 42 (Table 3.3). Whereas no dif-
ference was observed on Day 21, administration of Antibiotic Growth Promoters (AGP) 
was observed to have a significant effect on total LAB counts on Day 42 (P = 0.021), 
with the recovery of total LAB being greater from broilers administered VM than from 
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broilers which were not administered an AGP. Although a significant main effect 
was not observed for Feed additive administration on Day 21 or Day 42 (Table 3.3), re-
covery of C. perfringens in ADD treated broilers was similar to those administered 
AGPs on Day 21 when compared to untreated broilers (Figure 3.1 C). AGP administra-
tion was not observed to have a significant effect on Day 21, but fewer C. perfringens 
tended to be recovered from broilers administered VM than from untreated broilers (P = 
0.069). On Day 42, more C. perfringens were recovered from broilers administered VM 
than from those administered BMD or untreated broilers (P = 0.014).
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Table 3.3. Main effect of AGP and Feed Additive administration on gastrointestinal microbiota (log10 cfu g
-1).  
Main Effect  Total LAB  C. perfringens Salmonella Campylobacter E. coli 
D 21 D 42 D 21 D 42 D 21 D 42 D 21 D 42 D 21` D 42 
AGP 
        
  
Control 7.67 7.67b 3.11a 2.16b 0.24 0.00 2.01 2.05b 7.10 6.48b 
BMD1 7.85 7.88ab 2.77ab 2.24b 0.32 0.12 1.56 2.32ab 7.48 6.40b 
Virginiamycin2 8.10 8.33a 2.43b 2.73a 0.01 0.00 2.12 3.27a 7.39 7.34a 
Feed Additive           
Control 7.67b 8.05 2.92 2.43 0.15 0.00 2.01 2.73 7.20 6.91 
Feed Additive3 8.08a 7.86 2.61 2.33 0.23 0.07 1.79 2.35 7.44 6.57 
P-values           
AGP 0.151 0.021 0.069 0.014 0.259 0.320 0.484 0.042 0.429 0.050 
Feed Additive 0.028 0.330 0.183 0.544 0.636 0.321 0.567 0.351 0.350 0.313 
AGP×Feed Additive 0.867 0.454 0.717 0.921 0.216 0.374 0.940 0.040 0.127 0.952 
Pooled SEM 0.094 0.102 0.119 0.085 0.080 0.037 0.196 0.222 0.126 0.176 
a,b Different superscripts within columns indicate means are significantly different  (P ≤ 0.05)  
1Bacitracin Methylene Dialicylate; 2Virginiamycin (20 g t-1); 3DFM + XAP; 
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Figure 3.1. Enumeration of Gram-positive bacteria from broiler chickens. Total 
LAB were enumerated from the cecum of broiler chicks at (A) Day 21 and (B) Day 42 
post-hatch. C. perfringens was enumerated from the small intestine of broiler chicks at 
(C) Day 21 and (D) Day 42 post-hatch. White bars (control); Gray bars (ADD). Counts 
are reported as the mean ± SEM log10 CFU g
-1 digestive contents from 9 broiler chickens 
per treatment. Different letters above bars indicate means are significantly different (P ≤ 
0.05). 
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 3.3.1.2 Gram-negative Bacteria. The administration of AGPs or ADD resulted in 
no difference in the recovery of Salmonella (Table 3.3). Indeed, recovery of Salmonella 
was near the limit of detection for all treatment groups (Figure 3.2 A-B). Although no 
significant difference was observed in the recovery of Campylobacter on Day 21, a sig-
nificant main effect for AGP administration was detected with more Campylobacter be-
ing recovered from broilers administered VM than from untreated broilers (P = 0.042) 
on Day 42 (Table 3.3). Additionally, a significant AGP × Feed Additive interaction (P = 
0.04) was observed on Day 42. In broilers administered BMD, fewer Campylobacter 
were recovered from ADD treated broilers (P = 0.012) than from those that did not (Fig-
ure 3.2 D). Although, no significant difference was observed in the recovery of E. coli 
on Day 21, recovery of E. coli was greater from broilers administered VM than from 
others (P = 0.05) on Day 42. 
 Associations between the relative abundance of microorganisms in the gastroin-
testinal tract of chickens were also evaluated (not shown). Strong positive associations 
were detected between counts of total LAB and E. coli on Day 21 (r = 0.599, P < 0.001) 
and Day 42 (r = 0.522, P < 0.001). A moderate negative correlation was also detected 
between LAB and Salmonella on Day 42 (r = -0.290, P = 0.034). Lastly, counts of LAB 
and Campylobacter on Day 21 tended to correlate moderately (r = 0.263, P = 0.055), 
whereas LAB and Campylobacter counts were found to be correlate moderately (r = 
0.362, P = 0.007) on Day 42. No other significant correlations between groups of micro-
organisms were observed. 
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Figure 3.2. Enumeration of Gram-negative bacteria from broiler chickens. Salmo-
nella were enumerated from the cecum of broiler chicks at (A) Day 21 and (B) Day 42 
post-hatch. C. jejuni were enumerated from the cecum of broiler chicks at (C) Day 21 
and (D) Day 42 post-hatch. E. coli were enumerated from the cecum of broiler chicks at 
(E) Day 21 and (F) Day 42 post-hatch. White bars (control); Gray bars (ADD). Counts 
are reported as the log10 CFU g
-1 digestive contents from 9 broiler chickens per treat-
ment. Different letters above bars indicate means are significantly different (P ≤ 0.05). 
Different letters above bars indicate means are significantly different (P ≤ 0.05).  
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3.3.4 Feed Conversion 
The effect of the experimental treatments on the growth performance and feed 
conversion of broiler chickens in this study has been reported comprehensively in a sep-
arate publication (235). Feed conversion ratio of broiler chickens reported previously is 
summarized in Table 3.1. Overall, administration of ADD improved early (D 0-21) (P = 
0.002), late (D 22-42) (P = 0.005), and cumulative FCR (D 0 -42) (P < 0.001) when 
compared to the control, whereas AGP administration improved only late (P = 0.016) 
and cumulative FCR (P = 0.015). Administration of ADD improved early feed conver-
sion (P = 0.007) in unmedicated and VM-fed broilers but had no additional effect in 
broilers administered BMD. 
 Associations between populations of gastrointestinal microorganisms with feed 
conversion were evaluated (Table 3.4). Negative correlations (P < 0.05) were detected 
between total LAB counts on Day 21 and early FCR (Day 0 – 21) and between total 
LAB counts on Day 42 and late FCR (Day 21 -42). Additionally, total LAB on Day 21 
tended to correlate negatively (P < 0.1) with late and cumulative FCR (Day 0 – 42) and 
total LAB on Day 42 tended to correlate with cumulative FCR. A moderate positive cor-
relation was observed between counts of C. perfringens on Day 21 (P < 0.01) with late 
and cumulative FCR. Overall, these data suggest that FCR is lowest in broilers with 
greater counts of total LAB in the cecum and fewer counts of C. perfringens in the il-
eum. No associations were detected between FCR and Salmonella or E. coli. However, a 
strong negative correlation was detected between counts of Campylobacter on Day 42 
with late and cumulative FCR.  
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Table 3.4. Correlation of bacterial counts with FCR 
Bacterial Counts 
(log10 CFU g
-1) 
FCR (Feed:Gain) 
D 0-21 D 22-42 D 0-42 
Total LAB     
Day 21 r 
P 
-0.287 
0.035 
-0.237 
0.085 
-0.247 
0.072 
Day 42 r 
P 
-0.040 
0.773 
-0.278 
0.042 
-0.265 
0.053 
C. perfringens     
Day 21 r 
P 
0.186 
0.177 
0.339 
0.003 
0.405 
0.002 
Day 42 r 
P 
0.213 
0.123 
-0.019 
0.892 
0.014 
0.921 
C. jejuni     
Day 21 r 
P 
0.069 
0.621 
-0.114 
0.410 
-0.092 
0.509 
Day 42 r 
P 
-0.098 
0.479 
-0.428 
0.001 
-0.400 
0.003 
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3.4 DISCUSSION 
The objective of this study was to investigate the co-administration of Direct-Fed 
Microorganisms (DFM) and exogenous enzymes in broiler chickens as a potential alter-
native to and in addition to the use of antibiotic growth promoters (AGP). Although 
AGP have been widely used in the production of poultry and other livestock, the demand 
for antibiotic free (ABF) livestock production has increased due to consumer and regula-
tory concerns over the development of antibiotic resistant bacteria (199). Because the 
growth promoting activities of AGPs are a result of their effects on the gastrointestinal 
microbiota, the microbiota is likely to be an important target for the development of al-
ternatives to antibiotics. The gastrointestinal microbiota is increasingly recognized as an 
important modulator of human and animal health (239). Additionally, an important role 
of the microbiota is to augment host metabolism through the conversion of undigested 
feed components to bioavailable products that can subsequently be utilized by the host 
(23, 61). The effects of their administration on the gastrointestinal microbiota and in pro-
moting growth performance suggests DFM and exogenous enzyme as potential alterna-
tives to AGPs. The administration of DFMs in livestock has been demonstrated to im-
prove growth performance at levels similar to AGPs (16, 156) and reduce colonization 
of human food-borne and poultry pathogens in the gastrointestinal tract of poultry (215-
217). Exogenous enzymes are used routinely in animal feeds to improve digestibility of 
poorly digested feed constituents (Zanella, et al., 1999) and reduce their anti-nutritive ef-
fects (240). Additionally, the products of their hydrolysis may serve as substrates which 
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promote the growth or activities of beneficial bacteria (231). Indeed, the potentially syn-
ergistic effects of the co-administration of DFM and exogenous enzymes on growth per-
formance have been demonstrated previously (Murugesan and Persia, 2015). In this 
study, we evaluated the effect of the administration of a feed additive (ADD) composed 
of a DFM product containing spores of three Bacillus amyloliquefaciens strains and an 
XAP enzyme blend on the gastrointestinal microbiota and growth performance of broiler 
chickens fed diets with and without AGP. 
Administration of ADD improved feed efficiency of broiler chickens at levels 
similar to AGP, suggesting the co-administration of the DFM and enzyme blends may be 
a potentially important component of an ABF management program. The growth pro-
moting activities of DFM and exogenous enzymes has been widely demonstrated. De-
spite dramatic reductions in their use, AGPs are still widely administered in poultry pro-
duction, and administration of products to further improve growth in AGP-fed animals is 
also of interest. In this study, administration of ADD did further improve feed efficiency 
in broilers administered VM suggesting co-administration of DFM and enzyme blends 
may provide additional benefits to growth performance in antibiotic-fed broiler chickens.  
In this study, administration of ADD increased counts of Lactic Acid Bacteria 
(LAB) on Day 21 (P = 0.028), whereas AGP administration increased LAB counts only 
on Day 42 (P = 0.021). Although the difference was not significant in previously pub-
lished work, ADD administration has been demonstrated to increase LAB counts in the 
gastrointestinal tract of broiler chickens (234). Administration of Direct-Fed B. amylo-
liquefaciens (241) and xylanase (242) individually has been demonstrated previously to 
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increase LAB in the gastrointestinal tract and improve growth performance of broiler 
chickens. Characterization of gastrointestinal microbiota of broilers fed conventional and 
ABF diets found no significant difference in total LAB counts between ABF broilers and 
those fed a diet containing BMD (243), suggesting AGP administration may have only 
minimal effect on total LAB. LAB isolated from non-animal environments, including 
starter cultures and fermented foods, are commonly found to be resistant to multiple an-
tibiotics including bacitracin (244-246) and virginiamycin (247, 248), suggesting the re-
sistance determinants are inherent rather than acquired (249, 250). 
In this study, the negative correlation of total LAB counts on Day 21 and Day 42 
with early (Day 0 – 21) and late (Day 22 – 42) FCR, respectively, suggests an important 
association between LAB and more efficient feed conversion (Table 3.4). The LAB are 
important inhabitants of the gastrointestinal tract and are generally recognized as benefi-
cial to poultry intestinal health (133, 176, 251). Cultures of LAB, particularly Lactoba-
cillus species, have been used widely as probiotics and their administration to broilers 
has been demonstrated to improve growth performance (94, 157, 176). Administration of 
probiotic LAB has been shown to reduce colonization of bacterial pathogens, including 
Clostridium (252) and Salmonella (73, 253), in the gastrointestinal tract, likely through 
competition for shared attachment sites in the mucosa (98) and production of anti-micro-
bial metabolites (30, 102). Additionally, measures of improved epithelial barrier function 
including increased villus height and villus height:crypt depth ratio in the duodenum and 
ileum (156) and increased mucus production (254) have been observed in broilers ad-
ministered probiotic LAB (255). 
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The positive correlation of C. perfringens counts on Day 21 with late and cumu-
lative FCR suggests that greater C. perfringens counts are associated with less efficient 
feed conversion (Table 3.4). In addition to promoting growth, BMD and VM are admin-
istered to control C. perfringens, suggesting the reduction of sub-clinical infections of 
this organism as a specific therapeutic target for the development of alternatives to AGP. 
Reduced weight gain and increased FCR have been reported when high numbers of C. 
perfringens were recovered from broilers (256, 257), and negative effects on growth per-
formance have been reported when broilers were experimentally infected with C. 
perfringens (258). Necrosis of epithelial tissues mediated by the multiple virulence fac-
tors of C. perfringens, including collagenolytic enzymes (256), NetB toxin (257), phos-
pholipase C(α-toxin) results in reduced nutrient absorption through the intestinal epithe-
lium (259). Additionally, the subsequent immune response and repair of epithelial tis-
sues further increases the nutritional cost of endogenous losses and results in decreased 
growth performance (260). Administration of ADD was demonstrated previously to sig-
nificantly reduce C. perfringens in the ileum and cecum of broiler chickens (234). Alt-
hough a similar reduction was not observed in this study, ADD administration did re-
duce C. perfringens to levels similar to AGP administration. Administration of Direct-
Fed-Bacillus has been previously demonstrated to reduce C. perfringens and improve 
FCR to levels similar to AGP administration (261, 262). However, xylanase administra-
tion was previously demonstrated not to have an effect on the recovery of C. perfringens 
(263). 
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A negative correlation was observed between C. jejuni counts and FCR (Table 
3.4). However, overall, the treatments evaluated in this study were not observed to affect 
colonization by Campylobacter and Salmonella. In the absence of an experimental infec-
tion, it is difficult to assess the efficacy of an intervention in reducing colonization by 
these human food-borne pathogens. Administration of Direct-Fed Bacillus has been 
demonstrated previously to reduce Campylobacter (264) and Salmonella (213, 216, 265) 
colonization in experimentally infected broilers. Additionally, co-administration of a 
DFM and xylanase was previously demonstrated to reduce shedding of Salmonella and 
improve FCR in experimentally infected broilers (232). In the current study, ADD ad-
ministration reduced Campylobacter counts in broilers fed diets containing BMD. Alt-
hough C. jejuni has been widely considered to be a commensal in poultry (266, 267), the 
understanding of its relationship with the avian host is complicated by reports of its abil-
ity to induce intestinal inflammation, reduce intestinal barrier function, and invade intes-
tinal epithelial tissues in poultry (268-270). An improved understanding of the ecologi-
cal niche filled by Campylobacter will inform the development of interventions to re-
duce colonization of this organism in the gastrointestinal tract of poultry in order to de-
crease the risk of Campylobacter-associated foodborne illness from poultry.  
In this study, we investigated the effect of the co-administration of Direct-Fed 
Bacillus and an enzyme blend on the gastrointestinal microbiota and feed efficiency of 
broiler chickens. We have demonstrated the ability of the feed additive (DFM + XAP) to 
improve feed efficiency and modify the gastrointestinal microbiota to be similar to the 
use of antibiotic growth promoters suggesting this and other similar additives may serve 
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as alternatives to sub-therapeutic use of antibiotics in poultry production. Additionally, 
we observed a potential additional benefit to growth performance from the co-admin-
istration of DFM and enzyme blends in antibiotic-fed broilers. We have observed moder-
ate to strong associations of Lactic Acid Bacteria, Clostridium perfringens, and Campyl-
obacter jejuni with feed conversion, suggesting potentially important roles of these or-
ganisms in gastrointestinal health or in the gastrointestinal fermentation community. Ad-
ditional research will be required in order to determine the degree to which populations 
of these organisms should serve as therapeutic targets for the development of products 
intended to replace AGPs. Although we have not evaluated measures of intestinal barrier 
function, the effects on the microbiota observed in this study suggest improved intestinal 
barrier function associated with increased LAB counts and decreased nutritional costs 
associated with decreased sub-clinical infection by C. perfringens may be an important 
mode of action for the benefits of these antibiotic alternatives. Because of the reliability 
and effectiveness of antibiotic growth promoters, it is unlikely that a single alternative 
product will match their efficacy. Thus, the continued development of antibiotic free 
management programs is likely required to replace AGPs in poultry production. 
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4. COMPARING THE EFFECTS OF TWO PHYTASES ON POPULATIONS OF 
 GASTROINTESTINAL MICROORGANISMS IN BROILERS  
 
4.1 INTRODUCTION 
 Phosphorus is an essential nutrient in poultry production (271) with dietary defi-
ciencies leading to excessive financial losses due to increased mortality (227, 272). 
Phytic acid (myo-inositol hexaphosphate) is an important plant phosphorus storage form 
and accounts for 50 - 80 % of total phosphorus present in cereal grains and legumes 
commonly used in livestock animal feeds (82, 83). However, phytate-phosphorus has 
low bioavailability and is underutilized due to the lack of phytate-degrading enzymes in 
mono-gastric livestock including poultry (84-86). Additionally, phytic acid exerts anti-
nutritive effects (272), sequestering essential cations including calcium, magnesium, 
iron, and zinc and reducing their bioavailability (273). 
 Phytases are phosphatases which catalyze the hydrolysis of phytic acid to myo-
inositol and inorganic phosphate (274). In-feed administration of microbial phytases to 
improve digestibility of phytic acid is widely used in the production of poultry and other 
livestock (275, 276). The resulting increases in phytate-phosphorus digestibility (272, 
277, 278) and reduction in the anti-nutritive effects (226, 279) of phytic acid are well 
documented. 
 The gastrointestinal microbiota of the chicken is recognized to be a complex 
community that is a potentially important therapeutic target for the promoting health in 
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the chicken.  Its composition has been demonstrated to  change in response  to many fac-
tors including antibiotics (280), gender (281), age (44), and diet (40, 282, 283). The 
shifts in the composition of microbial communities can potentially produce the benefi-
cial effects including  improved feed conversion (284), reduced mortality (69) or have 
adverse effects, including increase feed intake (285) and proliferation of pathogenic or-
ganisms (286). Composition of feed (287), available phosphorous (288, 289), and 
phytase administration (282, 284) have been demonstrated to affect the composition of 
the bacterial communities present in the gastrointestinal tract of monogastric animals. 
Metzler-Zebeli Et al (290) demonstrated that increased available calcium and phytate-
phosphate from phytase reduced counts of some Lactic Acid Bacteria, while increasing 
strict anaerobic bacteria. In this study, we investigated the effects of two phytases ad-
ministered at two inclusion levels on growth performance and populations of gastrointes-
tinal microorganisms in broiler chickens fed a diet with reduced available phosphorus 
over a 42-day period.  
4.2. MATERIALS AND METHODS 
4.2.1 Experimental Design 
 Male broilers (Cobb 500, n = 2580) were obtained from a commercial hatchery 
on day of hatch, randomly assigned to treatment pens with similar starting weights, and 
provided experimental feed and water ad libitum for the duration of the study. Experi-
mental animals were allocated to 6 experimental treatment groups with 10 replicate pens 
of 43 broiler chicks arranged as a complete randomized block design. Experimental 
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treatment groups were fed experimental rations formulated to contain adequate phos-
phate as a Reference diet (REF) (aP%. Starter 0.45; Grower 0.41; and Finisher 0.36), a 
Reduced phosphate diet (RED) (aP%, Starter 0.277; Grower 0.237; and Finisher 0.186), 
and a Reduced phosphate diet supplemented with one of two phytases. The commercial 
phytases used in this study are composed of a mutant histidine acid phosphatase derived 
from Buttiauxella sp. (291) expressed in Trichoderma reesei (Phy 1) and a bacterial 6-
phytase from the histidine acid phosphatase family expressed in Aspergillus niger (Phy 
2), at 500 U kg-1 and 1,000U kg-1 feed (Table 4.1). All animal care and experimental 
procedures were performed in accordance with protocols approved by the Texas A&M 
University Institutional Animal Care and Use Committee.  
  
Table 4.1. Experimental Treatments of Two Phytases on Broiler Chickens 
Group 
Treatments 
aP (%) (S/G/F) Phytase Inclusion Rate 
Reference Diet 0.45/0.41/0.36 - - 
Reduced Diet 0.277/0.237/0.186 - - 
Phytase 1 – Low 0.277/0.237/0.186 Phytase 1 500 U kg-1 
Phytase 2 – Low 0.277/0.237/0.186 Phytase 2 500 U kg-1 
Phytase 1 – High 0.277/0.237/0.186 Phytase 1 1000 U kg-1 
Phytase 2 – High 0.277/0.237/0.186 Phytase 2 1000 U kg-1 
    
 62 
 
 
4.2.2 Bacterial Enumeration 
 At 21 and 42 days post-hatch, a single chicken of approximately mean pen 
weight was selected from each replicate pen, euthanized, and necropsied for the collec-
tion of tissues for the enumeration of gastrointestinal microorganisms. The ceca and a 
section (~ 6 cm) of the ileum centered on the midpoint between Meckel’s diverticulum 
and the ileocecal junction were dissected aseptically from each selected chicken. Ileal 
specimens were homogenized and diluted using Fluid Thioglycolate Medium (FTM; 
BD, Franklin Lakes, NJ), whereas cecal specimens were homogenized and diluted using 
sterile phosphate buffered saline (PBS; Fisher Scientific, Pittsburgh, PA). Campylobac-
ter jejuni was  enumerated from the ceca using Campy Cefex agar (Hardy Diagnostics, 
Santa Maria, California) incubated in 10% CO2 at 42 
oC; total Lactic Acid Bacteria 
(LAB) were enumerated from the ileum and ceca  using deMan, Rogosa, and Sharpe 
agar (MRS; BD) supplemented with 100 µg∙mL−1 cycloheximide (Amresco, Solon, OH) 
incubated in 10 % CO2 at 37 
oC; and Clostridium perfringens from the ileum using Tryp-
tose Sulphite Cycloserine Egg Yolk overlay agar (TSC-EY; BD) incubated anaerobi-
cally (Coy Laboratory Products, Grass Lake, MI) at 37 oC. C. jejuni was selectively en-
riched from cecal specimens using Bolton’s Enrichment Broth (BEB, Hardy Diagnostic) 
incubated at 42 oC for 24 h followed by isolation using Campy Cefex agar, and C. 
perfringens was selectively enriched from the ileal-FTM homogenate incubated anaero-
bically at 37°C for 24 h followed by culturing using Iron Milk Medium incubated at 
46oC for 3 h. Presumptive C. perfringens were confirmed using Iron Milk Medium. 
Specimens for which there were no colonies appearing on enumeration plates but were 
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positive by selective enrichment were assigned the lower limit of detection, 100 cfu g-1 
for statistical analysis. 
4.2.3 Statistical Analysis 
Bacterial counts were log10 transformed for analysis and reported as the mean ± 
SEM log10 cfu g
-1 digestive contents from 10 replicate pens per treatment. Data for all 
treatments were analyzed using one-way ANOVA, while data for phytase-treated groups 
were also analyzed using factorial ANOVA with main effects for phytase, inclusion rate, 
and phytase  inclusion rate. Significantly different means (P ≤ 0.05) were separated 
using Duncan’s multiple range test post hoc. Associations between bacterial counts and 
feed conversion ratio (FCR) were evaluated by pens using Pearson’s r. 
4.3 RESULTS 
4.3.1 Gastrointestinal Microbiota 
 4.3.1.1 Total Lactic Acid Bacteria.  
 4.3.1.1.1 Ileum 
 A significant treatment effect was observed from analysis using One-way 
ANOVA on counts of total LAB in the ileum at Day 21 (P = 0.02) (Figure 4.1A) and 
Day 42 (P = 0.02) (Figure 4.1B) post-hatch (Table 4.2). On Day 21, counts of total 
LAB were greatest when broilers were fed the Reference diet and diets containing Phy 2. 
Whereas on Day 42, counts of total LAB were greatest when broilers were fed the Re-
duced diet and the diet containing Phy 2. Total LAB counts were greater in broilers ad-
ministered 500 U kg-1 Phy 2 as compared to those administered 500 U kg-1 Phy 1 on Day 
21 (P = 0.002), whereas total LAB counts were greater in broilers administered 1000 U  
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Figure 4.1. Enumeration of Total LAB in the ileum. Total LAB were enumerated 
from the small intestine of broiler chicks at (A) Day 21 and (B) Day 42 post-hatch, fol-
lowed by main effects between Total LAB and phytase sources; and main effects be-
tween Total LAB and dose levels (C/D). Counts are reported as the log10 CFU g
-1 diges-
tive contents from 10 broiler chickens per treatment. Different letters above bars indicate 
means are significantly different (P ≤ 0.05).  
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kg-1 Phy 2 as compared to those fed 1000 U kg-1 Phy 1 on Day 42 (P = 0.027) (Figure 
4.1B).  
 A significant main effect of phytase on total LAB counts in the ileum was ob-
served on Day 21, with more LAB having been recovered from broilers fed diets con-
taining Phy 2 as compared to those fed diets containing Phy 1 (P = 0.01) (Figure 4.1C). 
A significant main effect of phytase on total LAB counts was not observed for Day 42 
post-hatch. However, on Day 42, recovery of total LAB tended to be greater when broil-
ers were fed diets containing Phy 2 (P = 0.07) (Figure 4.1D). A significant main effect 
of the level of phytase inclusion was not observed for LAB counts on Day 21 or Day 42  
post-hatch. However, on Day 42, recovery of total LAB tended to be greater when broil-
ers were fed diets containing 1000 U kg-1 phytase as compared to those fed diets contain-
ing 500 U kg-1 phytase (P = 0.098) (Figure 4.1D). No significant Phytase × Dose inter-
action was observed throughout the 42 Day trial.  
 4.3.1.1.2 Cecum 
 A significant treatment effect was observed from analysis using One-way 
ANOVA on counts of total LAB in the cecum at Day 21 (P = 0.01) (Figure 4.2A). 
Counts of total LAB were greatest when broilers were fed diets containing 500 U kg-1 or 
1000 U kg-1 of Phy 2 and the Reduced diet, whereas total LAB counts were lower when 
broilers were fed the Reference diet. A significant treatment effect was not observed on 
counts of total LAB in the cecum at Day 42 post-hatch (P = 0.36) (Figure 4.2B). How-
ever, counts of total LAB tended to be greater when broilers were fed diets containing 
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500 U kg-1 Phy 1 (P = 0.077), 1000 U kg-1 Phy 1 (P = 0.092), and 1000 U kg-1 Phy 2 (P 
= 0.062) (Figure 4.2B) as compared to broilers fed the Reference diet.  
 
Figure 4.2. Enumeration of Total LAB in the cecum. Total LAB were enumerated 
from the cecum of broiler chicks at (A) Day 21 and (B) Day 42 post-hatch, followed by 
main effects between Total LAB and phytase sources; and main effects between Total 
LAB and dose levels (C/D). Counts are reported as the log10 CFU g
-1 digestive contents 
from 10 broiler chickens per treatment. Different letters above bars indicate means are 
significantly different (P ≤ 0.05).  
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Table 4.2. Effects of phytase on gastrointestinal bacteria (log10 cfu g
-1) 
Treatments 
 Ileum Cecum 
 Total LAB5  C. perfringens  Total LAB  C. jejuni 
Diet Phy2 Dose3  Day 21 Day 42  Day 21 Day 42  Day 21 Day 42  Day 21 Day 42 
               
REF1 - 0  7.17a 7.26bc  2.90 3.55  7.94a 8.15  3.56 6.51 
               
 Red2 - 0  6.77ab 8.03ab  2.55 2.50  8.52abc 8.32  4.01 6.30 
 
Red 1 500  6.24b 7.07c  2.89 2.87  8.07cd 8.53  4.28 7.00 
 
Red 2 500  7.59a 7.30bc  2.82 2.73  8.58ab 8.36  4.50 6.28 
 
Red 1 1000  7.07ab 7.25bc  3.32 3.48  8.37bcd 8.53  4.44 6.40 
 
Red 2 1000  7.47a 8.08a  3.11 3.33  8.84a    8.55  4.30 6.50 
 
Pooled SEM  0.13 0.11  0.09 0.14  0.08 0.018  0.14 0.08 
 
P-value  0.02 0.02  0.22 0.20  0.01 0.36  0.32 0.17 
 
1 Reference Diet (REF); 2 Reduced Phosphate (RED); 3 Phytase type; 4 Phytase inclusion, U kg -1 ; 5 Lactic Acid Bacteria 
a-d Different superscripts within columns indicate means are significantly different (P≤0.05) 
 68 
 
 A significant main effect of phytase on counts of total LAB in the cecum was ob-
served on Day 21 (P = 0.008) (Figure 4.2C), with more LAB recovered from broiler fed 
diets containing Phy 2 as compared to those fed diets containing Phy 1. However, a sig-
nificant main effect was not observed on Day 42 post-hatch (P = 0.66) (Figure 4.2D). A 
significant main effect of the level of phytase inclusion on counts of total LAB in the ce-
cum was not observed for Day 21 or Day 42 post-hatch (Figure 4.2C/D). However, 
more LAB tended to be recovered from broilers fed diets containing 1000 U kg-1 phytase 
as compared to those fed diets containing 500 U kg-1 (P = 0.099) (Figure 4.2C). No sig-
nificant Phytase × Dose interaction was observed throughout the 42 Day trial. 
 4.3.1.2 Clostridium perfringens. A significant treatment effect was not observed 
from analysis using One-way ANOVA on counts of Clostridium perfringens in the il-
eum of broilers on Day 21 (P = 0.22) or Day 42 (P = 0.20) (Table 4.2) post-hatch. How-
ever, C. perfringens counts were lowest from broilers fed the Reduced diet as compared 
to the remaining treatment groups on Day 21 and Day 42 (Figure 4.3A/B). Although the 
overall treatment effect was not significant, more C. perfringens were recovered from 
broilers fed the Reference diet as compared those fed the reduced diet on Day 42 (P = 
0.039). Additionally, C. perfringens counts tended to be greater when broilers were fed 
diets containing 1000 U kg-1 of either Phy 1 (P = 0.052) or Phy 2 (P = 0.098) (Figure 
4.3B) as compared those fed the Reduced diet. Significant main effects of phytase on 
counts of Clostridium perfringens in the ileum were not observed on Day 21 or Day 42 
(Figure 4.3C/D). However, more C. perfringens tended to be recovered from broilers 
fed diets containing 1000 U/kg phytase as compared to those fed diets containing 500  
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Figure 4.3.  Enumeration of Clostridium perfringens in the ileum. C. perfringens 
were enumerated from the small intestine of broiler chicks at (A) Day 21 and (B) Day 42 
post-hatch, followed by main effects between Total C. perfringens and phytase sources; 
and main effects between C. perfringens and dose levels (C/D). Counts are reported as 
the log10 CFU g
-1 digestive contents from 10 broiler chickens per treatment. Different 
letters above bars indicate means are significantly different (P ≤ 0.05).  
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U/kg phytase on Day 21 (P = 0.075) and Day 42 (P = 0.099) (Figure 4.3C/D). No sig-
nificant Phytase × Dose interaction was observed throughout the 42 Day trial.  
 4.3.1.3 Campylobacter jejuni. A significant treatment effect was not observed 
from analysis using One-way ANOVA on counts of Campylobacter jejuni in the cecum 
of broilers on Day 21 (P = 0.32) and Day 42 (P = 0.17) (Figure 4.4A/B). Although the 
difference was not significant, fewer C. jejuni were recovered when broilers were ad-
ministered the Reference diet as compared to the other treatments on Day 21. No signifi-
cant main effects of phytase or level of phytase inclusion on the recovery of C. jejuni 
from the cecum were observed from on Day 21 or Day 42 (Figure 4.4C/D).  
4.3.2 Correlation of Bacterial Counts and Growth Performance 
 The effect of the experimental treatments on feed conversion and tibia ash of 
broiler chickens is summarized in Table 4.3 Overall, administration of Phytase im-
proved early (Day 0-21) (P = 0.007), late (Day22-42) (P < 0.001), and cumulative FCR 
(cFCR) (P < 0.001) when compared to the Reduced diet, and to levels statistically simi-
lar to Reference diet. Administration of 1000 U kg-1 Phy 1 had the greatest improvement 
in feed conversion and recovered Tibia Ash weight when compared to other phytase 
treatments and the Reference diet. Furthermore Phy 1 was statistically similar to the Ref-
erence diet. Likewise, both inclusion rates of Phy 2 improved early (Day 0-21) FCR to 
similar levels of 1000 U kg-1 Phy 1 and the Reference diet.  
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Figure 4.4 Enumeration of Campylobacter jejuni in the cecum. C. jejuni were enu-
merated from the cecum of broiler chicks at (A) Day 21 and (B) Day 42 post-hatch, fol-
lowed by main effects between C. jejuni and phytase sources; and main effects between 
C. jejuni and dose levels (C/D). Counts are reported as the log10 CFU g
-1 digestive con-
tents from 10 broiler chickens per treatment. Different letters above bars indicate means 
are significantly different (P ≤ 0.05).  
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  Table 4.3. Select growth performance measures of broiler chickens 
Treatments  FCR (Feed:Gain)4  Tibia Ash 
aP1 Phy2 Dose3  D 00-21 D 22-42 cFCR5  Ash % Wt(g) 
          
REF - 0  1.363b 1.792c 1.776c  51.90a 0.924ab 
          
RED - 0  1.448a 1.858a 2.041a  47.27b 0.599d 
          
RED 1 500  1.386ab 1.818bc 1.824bc  51.06a 0.880bc 
          
RED 2 500  1.376b 1.828b 1.849b  51.32a 0.862c 
          
RED 1 1000  1.372b 1.797c 1.776c  51.65a 0.947a 
          
RED 2 1000  1.402ab 1.804bc 1.806bc  51.36a 0.936a 
          
 Pooled SEM  0.005 0.005 0.014  0.24 0.018 
         
 P-value  0.007 <0.001 <0.001  <0.001 <0.001 
          
1 Available phosphate; 2 Phytase type; 3 Phytase inclusion, U kg-1; 4 cumulative FCR; 5Body weight 
corrected cumulative FCR 
a-d Different superscripts within columns indicate means are significantly different (P ≤ 0.05) 
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Associations between populations of gastrointestinal microorganisms with feed conver-
sion were evaluated (Table 4.4). A moderate positive correlation (P = 0.036) was 
detected between total LAB in the ileum on Day 42 and early FCR, in addition to a posi-
tive trending correlation with cumulative FCR (P = 0.082). Additionally, another weak 
positive correlation (P = 0.038) was detected between total LAB in the cecum on Day 42 
and early FCR. Furthermore, total LAB in the ileum on Day 42 tended to correlate nega-
tively (P < 0.1) with Tibia Ash % and Tibia Ash weight. Weak negative correlations 
were detected between total C. perfringens counts on Day 21 (P = 0.030) and Day 42 (P 
= 0.027) with early FCR (Day 0 – 21) and cumulative body weight corrected FCR, re-
spectively. However, weak positive correlations were detected between total C. 
perfringens counts on Day 21(P = 0.006) Tibia Ash weight and Day 42 (P = 0.047) with 
Tibia Ash %. No associations were detected between FCR, and Campylobacter, and no 
associations were detected between Tibia Ash and C. jejuni.  
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Table 4.4. Correlation of bacterial counts with select growth performance measures 
Bacterial Counts  
FCR (Feed:Gain)1 
 
Tibia Ash 
(Log10 CFU g
-1)  D 00-21 D 22-42 cFCR2  Ash % Wt(g) 
Ileum        
 Total LAB3        
   Day 21 r -0.016 -0.055 -0.096  0.233  0.145 
 P  0.903   0.678  0.466   0.073  0.269 
        
   Day 42 r  0.272  0.016  0.226  -0.232 -0.237 
    P  0.036  0.903  0.082   0.074  0.068 
 C. perfringens        
   Day 21 r -0.280 -0.203 -0.245   0.239  0.348 
 P  0.030  0.120  0.059   0.066  0.006 
        
   Day 42 r  0.110 -0.226 -0.286   0.257  0.167 
    P  0.401  0.083  0.027   0.047  0.201 
Cecum        
 Total LAB3        
   Day 21 r  0.101 -0.032  0.036  -0.050 -0.061 
 P  0.444  0.807  0.784   0.703  0.643 
        
   Day 42 r  0.268  0.055 -0.009   0.129  0.053 
 P  0.038  0.676  0.943   0.326  0.689 
 C. jejuni        
   Day 21 r  0.063 -0.183 -0.161   0.140 -0.012 
 P  0.631  0.161  0.218   0.288  0.926 
        
   Day 42 r -0.015 -0.056 -0.135   0.168  0.152 
 P  0.907  0.673  0.302   0.200  0.248 
        
1 Mortality corrected FCR; 2 cumulative FCR; 3 LAB, Lactic Acid Bacteria 
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4.4 DISCUSSION 
The objective of this study was to compare the effects of two exogenous phytases 
administered at two inclusion levels on growth performance and the populations of gas-
trointestinal microorganisms of broiler chickens. In-feed administration of microbial 
phytases to improve the digestibility of phytic acid is used widely in the production of 
poultry (276, 292). Although the resulting increase in phytate-phosphorus digestibility 
and reduction in the anti-nutritive effects of phytic acid are well documented (226, 278), 
effects of available phosphate and phytase supplementation on the gastrointestinal mi-
crobiota have not been widely investigated. The gastrointestinal microbiota is increas-
ingly recognized as an important modulator of human and animal health (239). Addition-
ally, the products of phytate hydrolysis may serve as substrates which promote or limit 
the growth activities of bacteria (231). It has been suggested that an increase in strict an-
aerobic bacteria may be associated with greater phosphorous availability in the lumen of 
the gastrointestinal tract (284, 290). Furthermore, greater calcium and phosphorous 
availability from the hydrolysis of phytate in the small intestine of swine was demon-
strated reduce populations of lactobacilli (290). The concentration of bioavailable phos-
phorous and calcium has been demonstrated to modulate the microbiota of monogastric 
animals, including murine (293), porcine (288), and poultry models (294). In this study, 
we evaluated the effect of the administration of two phytases at two inclusion levels on 
growth performance, bone ash, and the populations of gastrointestinal microorganisms 
of broiler chickens fed a diet with reduced available phosphorous over a 42-day growth 
period. 
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Administration of phytases improved growth performance of broiler chickens to 
a level similar to that for those fed a diet adequate in phosphorus. Phosphatases and 
phytase are commonly used in poultry production (278, 292), and their effects in enhanc-
ing performance and nutrient availability is widely known (23, 220, 292) and. There are 
many sources of microbial phytases (292) including Gram-negative bacteria (295), 
Gram-positive bacteria (296, 297), and molds (298). The efficacy of phytases may de-
pend on their specificity and mode of action (299, 300). Phytases catalyze the hydrolysis 
of phosphate groups from specific positions of  phytic acid, with preference of the phos-
phate at the IP6 position,  to IP1 in descending order (301, 302). Some bacterial phytases 
have demonstrated affinity for IP6 and IP5 with high resistance to proteolytic digestion 
compared to fungal phytases (303). Furthermore, optimal phytase activity differs be-
tween microbial species and pH values (304, 305) both in vitro (306) and in vivo (307). 
Similarly, a histidine acid-phosphatase from Aspergillus niger was demonstrated to re-
lease all six phosphates from the myo-inositol hexakisphosphate, whereas a histidine 
phosphatase from E. coli only released 5 of the 6 under strict in vitro conditions (301). 
These factors suggest the possibility that there are appropriate phytases for each live-
stock animal (302), which may further be complicated by dietary-related factors, specifi-
cally plant-based feed ingredients (302, 308). In this study, the lowest FCR amongst the 
phytase treatments was seen with 1000 U kg-1 Phy 1 (Table 4.3).  In actuality, some 
phytases may depend on availability of metal-free phytate or calcium-phytate substrates 
(309), in addition to the previously mentioned factors. Furthermore, similar commercial 
phytase products have different optimal conditions. Phyzyme® an E. coli origin phytase  
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from Danisco Animal Nutrition has an optimal pH of 4.5 and temperature of 55 ˚C 
(302), whereas the Buttiauxella product Axtra® has an optimal pH range of 3.5-4.5 and 
temperature of 60 ˚C (302). It is possible that the efficacy of these phytases differ in the 
small intestine of a broiler chicken pH 6.0-6.5 (310) and 41 ˚C (311). Which could ex-
plain the difference between the two histidine phytases used in this current study.In this 
study, the positive associations with FCR were observed between counts of total LAB in 
the ileum (P = 0.036) and cecum (P = 0.038) at Day 21 post-hatch (Table 4.4). This is 
contradictory to previous reports reporting LAB improving growth performance in broil-
ers (94, 157, 176). However, LAB make up a significant population of the gastrointesti-
nal tract (44, 294). Furthermore, they are believed to be important inhabitants of the gas-
trointestinal microbiota, and are generally recognized as beneficial to poultry health 
(133, 251). It may be possible that specific genera that comprise LAB are responsible for 
improved growth and general commensalism to the broiler chicken, whereas the remain-
ing genera may not provide a benefit to the host. Additionally, it has been previously 
demonstrated that the beneficial LAB, lactobacilli were reduced with increased bioavail-
ability of calcium and phytate-P in swine (290). Perhaps this is another reason why re-
duced growth performance was observed. Also, it may be appropriate to explore if cer-
tain lactic acid producing bacteria reduce broiler growth performance, or at least reduce 
the effectiveness of phytase administration. The understanding of the role of the gastro-
intestinal microbiota and the role of specific microorganism in animal health is still con-
sidered to be in its infancy.  Thus, the role of specific LAB in potentially reducing 
growth performance is undetermined at this time. Although total LAB was greatest in 
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broilers administered Phy 2 compared to Phy 1 (Figure 4.3 and 4.4), LAB populations 
were still abundant in the unsupplemented treatment (Figure 4.1 and 4.2), suggesting 
the increased available phosphate from phytase supplementation being the primary fac-
tor in growth performance in this study.  
The negative correlations of C. perfringens counts were observed with early FCR 
and cumulative FCR (Table 4.4). Additionally, positive correlations between C. 
perfringens counts and Tibia ash was detected. Suggesting that 3 log10 CFU g
-1 of C. 
perfringens is associated with more efficient feed conversion and bone mineralization. 
Tibia ash % and weight are commonly used indicators of mineral adequacy in poultry, 
the primary nutrients that make up bone are calcium and phosphorus (312, 313). Poor 
mineralization is associated with poor nutrient absorption (314). However, reduced 
weight gain, poor mineralization and increased FCR is commonly reported when high 
numbers of C. perfringens are recovered from both naturally (315, 316) and experimen-
tally infected (258) broilers. Still, C. perfringens enumerated from broilers in all experi-
mental treatments was near or below 3 log10 CFU g
-1, far below C. perfringens levels as-
sociated clinical infections of necrotic enteritis at 5 log10 CFU g
-1 (317). Once phytase 
releases nutrients from phytate, those nutrients become available to both bacteria and 
broiler chicken (318). It is suggested that both calcium and phosphorus in combination is 
important to C. perfringens proliferation (319, 320) and toxin production (317), not 
phosphorous alone. Although phytase did not reduce C. perfringens levels in these ex-
perimental conditions, it was not unexpected. It may be possible that low quantities C. 
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perfringens fill an important ecological niche in the gastrointestinal microbiota of poul-
try. 
No correlations were observed between Campylobacter jejuni and FCR. Overall 
treatments evaluated in this study were not observed to affect colonization by C. jejuni. 
Although it is a human food-borne pathogen, C. jejuni has been suggested to be naturally 
occurring (321) and commensal in poultry (266, 267).  C. jejuni can serve as a hydrogen 
scavenger (322) potentially accelerating rate-limiting reactions during anaerobic fermen-
tations, suggesting an important ecological role of Campylobacter as commensal/mutu-
alistic microorganism in poultry.  
In this study, we compared the effects of two phytases administered on growth 
performance and selected gastrointestinal microbial populations. We observed the effi-
cacy of phytate hydrolysis by different phytase types affected microbial populations.  
Positive associations were observed between counts of Total LAB in the ileum with FCR 
and negative associations observed in C. perfringens counts with FCR. Although phos-
phate digestibility was not evaluated in this study, the observed associations suggest that 
the improved growth performance of broiler chickens was the result, at least in part, of 
the improved digestibility of phytate-phosphorous released by the phytase enzyme ad-
ministered to the broiler chickens. Whereas the microbial variations seen were perhaps 
affected by the released phytate-P and calcium. The effects observed are dependent on 
feed ingredients, feed composition, enzyme type, and concentration (282). Without a de-
fined microbiome for healthy broiler chickens fed a specific diet and enzyme, associa-
tions observed may be indicative of a small group, rather than an entire population. 
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Thus, the continued development of exogenous enzyme of microbial origin, and their ef-
fects on the host microbiota will be important to poultry production.  
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5. DOSE RESPONSE OF DIRECT-FED CLOSTRIDIUM BUTYRICUM  
MIYAIRI 588 ON POPULATIONS OF GASTROINTESTINAL 
 MICROORGANISMS IN BROILERS 
 
5.1 INTRODUCTION  
 Direct-Fed Microorganisms (DFM) are live microorganism fed to livestock ani-
mals for some presumed benefit associated with the microorganism (212). When admin-
istered to poultry, DFMs have been demonstrated to reduce colonization of poultry-asso-
ciated pathogens (216, 217) by competitive exclusion (5), promote growth of the host 
animal at levels similar to antibiotic growth promoters (AGP) (323), and improve 
measures of intestinal health and function (324). Because of the benefits of their use, 
DFMs have received significant interest as potential alternatives to AGP (158) in re-
sponse to increased regulation of antibiotics in livestock animal production (325). Alt-
hough DFMs are used widely in the production of many livestock species (15), their ef-
fectiveness is varied between host species. However, there are several reasons that ac-
count for mixed effectiveness, mode of action for many DFMs are not understood. Addi-
tionally, DFM species, age, and diet can impact study results (239, 326). These factors 
promote the need for additional research to identify more effective DFMs for each live-
stock species. 
 Spore-forming bacteria, including Bacillus spp. and others, are widely used as 
DFMs in livestock animal production (133, 327). Spore-forming DFMs have greater heat 
resistance and longer shelf-life compared to the Lactic Acid Bacteria (LAB) which have 
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been traditionally used as probiotics and DFMs (328). The resulting increased surviva-
bility during the feed pelleting process and their prolonged viability in the absence of re-
frigeration are important advantages to the application of spore-forming bacteria as pro-
biotics and DFMs (329, 330). Additionally, bacterial endospores are highly resilient to 
the deleterious environmental stresses of low pH and bile (331, 332) than vegetative bac-
teria in the gastrointestinal tract, allowing for a greater survivability and germination 
(329). Additionally, Direct-Fed spores have been demonstrated to germinate in the gas-
trointestinal tract, where they  transiently colonize the host and their activities may exert 
probiotic benefits (333).   
 Clostridium butyricum is a Gram-positive, spore-forming, obligate anaerobe 
commonly  isolated from soil and the human intestine (334, 335). Although pathogenic 
strains of C. butyricum have been characterized (336-338), there is significant interest in 
the use of non-virulent strains of C. butyricum as DFMs in poultry because of their abil-
ity to produce butyric acid as the major product of their primary metabolism (339-341). 
Administration of butyric acid to chickens has been demonstrated to increase villus 
height and surface area in the intestine (342), which is an important factor in nutrient uti-
lization and growth performance (343, 344). Administration of non-virulent C. butyri-
cum has been demonstrated to promote populations of Lactobacillus and Bifidobacte-
rium in mice (345) and broiler (346). Additionally, administration of C. butyricum has 
been demonstrated to improve measures of growth performance, antioxidation, and im-
mune function in broiler chickens (332, 346). 
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 Clostridium butyricum MIYAIRI 588 (CBM 588) is nonpathogenic because it 
lacks toxin production genes and other virulence factors associated with pathogenic 
Clostridium strains (347). Used as a probiotic culture in humans, it has been demon-
strated to reduce E. coli O157:H7 infections in mice (348) and antibiotic associated diar-
rhea caused by Clostridium difficile during H. pylori eradication therapy in humans 
(349). In this study, we evaluated the effects of the DFM C. butyricum MIYAIRI 588 on 
the gastrointestinal microbiota and growth performance of broiler chickens in order to 
determine its potential as a DFM culture for use in poultry production. 
5.2 MATERIALS AND METHODS 
5.2.1 Experimental Design 
 Male broilers (Cobb 500, n = 2640) were obtained from a commercial hatchery 
on day of hatch, randomly assigned to treatment pens with similar starting weights, and 
provided experimental feed and water ad libitum for the duration of the study. Experi-
mental animals were allocated to 5 experimental treatment groups with 12 replicate pens 
of 43 broiler chicks arranged as a complete randomized block design. Experimental 
treatment groups were fed an Untreated control diet; a diet containing bacitracin meth-
ylene disalicylate (BMD) (50 g ton-1 feed); or diets containing spores of Clostridium bu-
tyricum MIYAIRI 588 at inclusion levels of 1.25, 2.50, and 3.75 × 108 cfu kg-1 feed. All 
animal care and experimental procedures were performed in accordance with protocols 
approved by the Texas A&M University Institutional Animal Care and Use Committee.  
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5.2.2 Bacterial Enumeration  
 At 14 and 42 days post-hatch, three chickens of approximately mean pen weight 
were selected from each replicate pen, euthanized, and necropsied. The ceca and a sec-
tion (~ 6 cm) of the ileum centered on the midpoint between Meckel’s diverticulum and 
the ileocecal junction were dissected aseptically from each selected chicken, and col-
lected specimens were grouped by organ and pooled by pen. Ileal specimens were ho-
mogenized and diluted using Fluid Thioglycolate Medium (FTM; BD, Franklin Lakes, 
NJ), while cecal specimens were homogenized and diluted using sterile anaerobic dilu-
ent consisting of: 0.45% potassium dihydrogen phosphate (% w/v) (Sigma-Aldrich), 
0.6% sodium dihydrogen phosphate dodecahydrate (% w/v) (Sigma-Aldrich), 0.05% L-
cysteine hydrochloride monohydrate (% w/v) (Sigma-Aldrich), 0.05% Tween 80 (% v/v) 
(Sigma-Aldrich), and 0.05% agar (% w/v) (BD). Total Lactic Acid Bacteria (LAB), 
Bifidobacterium spp., C. perfringens, Total Gram-positive cocci, and total aerobic bacte-
ria were enumerated from the ileum using deMan, Rogosa, and Sharpe agar (MRS; BD) 
supplemented with 100 µg∙mL−1 cycloheximide, Bifidobacterium agar, Modified (BD), 
Tryptose Sulphite Cycloserine Egg Yolk overlay agar (TSC-EY; BD) (Amresco, Solon, 
OH), Sodium Azide Agar (BD), and Trypticase Soy agar (TSA, BD) respectively. Clos-
tridium butyricum was enumerated from the cecum using BL Agar (Nissui Pharmaceuti-
cal, Tokyo, Japan) supplemented with 2% sodium propanoate (% w/v) (Sigma-Aldrich), 
0.0002% sodium fluoride (% w/v) (Sigma-Aldrich), 5% defibrinated horse blood (% v/v) 
(Fisher Sci), 50 µg∙mL−1 Novobiocin, and 100 µg∙mL−1 D-cycloserine. Sodium Azide 
agar and TSA was incubated aerobically at 37oC for 24 h. MRS were incubated in 10% 
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CO2 at 42
oC and 37oC for 36 h., respectively. TSC-EY, modified Bifidobacterium agar 
and Clostridium butyricum Modified BL agar (Nissui) was incubated at 37oC anaerobi-
cally (Coy Laboratory Products, Grass Lake, MI) for 36 h. C. perfringens was selec-
tively enriched from the ileum using FTM homogenate incubated anaerobically at 37°C 
for 24 h followed by Iron Milk Medium incubated at 46oC for 3 h. Specimens for which 
there were no colonies appearing on enumeration plates but were positive by selective 
enrichment were assigned the lower limit of detection, 100 cfu g-1 for statistical analysis. 
Presumptive C. perfringens were confirmed using Iron Milk Medium. 
5.2.3 Statistical Analysis 
Bacterial counts were log10 transformed for analysis and reported as the mean ± 
SEM log10 cfu g
-1 digestive contents from 12 replicate pens per treatment. Data was ana-
lyzed using ANOVA. significantly different means (P ≤ 0.05) were separated using 
Duncan’s multiple range test post-hoc. Associations between bacterial counts and feed 
conversion ratio (FCR) were evaluated by pens using Pearson’s r. 
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5.3 RESULTS 
5.3.1 Enumeration of Gastrointestinal Bacteria  
 5.3.1.1 Clostridium butyricum. A significant treatment effect was not observed 
on counts of C. butyricum in the cecum of broilers on Day 14 (P = 0.167) or Day 42 (P = 
0.095) (Table 5.1 and Figure 5.1 A-B). Although C. butyricum MIYAIRI 588 admin-
istration was not observed to have a significant effect on Day 42,  
fewer C. butyricum tended to be recovered from broilers administered the BMD diet 
than remaining treatments (P < 0.10). The dose of C. butyricum MIYAIRI 588 adminis-
tered was not observed to affect the recovery of C. butyricum on Day 14 or Day 42 (Fig-
ure 5.1 A/B). However, C. butyricum MIYAIRI 588 inclusion rate tended to increase the 
recovery of C. butyricum on Day 42 (Table 5.1). 
 5.3.1.2 Total LAB. A significant treatment effect was observed on counts of total 
Lactic Acid Bacteria in the ileum at Day 14 post-hatch (P = 0.014) (Figure 5.1 C). 
Counts of total LAB were greater when birds were fed diets containing C. butyricum 
MIYAIRI 588 and BMD as compared to those fed the Untreated (UNT) diet. A signifi-
cant treatment effect was also observed on counts of total LAB in the ileum at Day 42 
post-hatch (P < 0.001) (Figure 5.1 D). Fewer total LAB were recovered from broilers 
fed the diet containing the 1× dose of C. butyricum MIYARI 588 than from broilers fed 
the other diets. The dose of C. butyricum MIYAIRI 588 administered was not observed 
to affect the recovery of total LAB on Day 14. However, a significant effect of C. butyri-
cum MIYAIRI 588 inclusion rate on counts of total LAB in the ileum was observed on 
Day 42 (P < 0.05), with more LAB recovered from broiler inclusion levels of 2× and 3× 
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Table 5.1. Effects of C. butyricum MIYAIRI 588 administration on gastrointestinal bacteria (log
10
 cfu g
-1
)  
  Cecum  Ileum 
    C. butryicum  Total LAB
2
   Bifidobacterium   Gram (+) Cocci   Total Aerobes   C. perfringens 
Treatment   D 14 D 42  D 14 D 42   D 14 D 42   D 14 D 42   D 14 D 42   D 14 D 42 
BMD Control
1
   7.60 6.84
y  8.26
a
 8.34
a
   6.32
bc
 7.23
b
   7.69
ab
 7.66
b
   8.01
xy 
7.76
b
   2.77 3.31
x 
Untreated Control (UNT)   7.80 7.31x  7.83
b
 8.59
a
   6.26
c
 7.39
ab
   7.42
b
 7.79
b
   7.53
y 
8.44
a
   2.88 2.74
xy 
CBM 588 1.25  10
8
 cfu kg
-1
   8.07 7.20
xy  8.41
a
 7.56
b
   7.03
a
 6.70
c
   7.95
a
 7.27
c
   8.19
x 
7.10
c
   2.55 2.53
y 
CBM 588 2.50  10
8
 cfu kg
-1
   7.65 7.14
xy  8.14
ab
 8.56
a
   6.73
ab
 7.73
a
   7.79
a
 8.23
a
   8.00
xy 
8.25
ab
   2.99 2.55
y 
CBM 588 3.75  10
8
 cfu kg
-1
   7.81 7.39
x  8.23
a
 8.70
a
   6.92
a
 7.51
ab
   7.97
a
 8.17
a
   8.01
xy 
8.14
ab
   3.34 2.82
xy 
                                     
Pooled SEM   0.065 0.068  0.055 0.076   0.080 0.088   0.054 0.072   0.072 0.101   0.135 0.093 
P   0.167 0.095  0.014 <0.001   0.004 <0.001   0.004 <0.001   0.060 <0.001   0.479 0.064 
r
2
   0.294 0.321  0.339 0.556   0.338 0.591   0.429 0.550   0.270 0.453   0.168 0.295 
1
BMD (50 g ton
-1
); 
2
Lactic Acid Bacteria 
a-c
Different superscripts within columns indicate means are significantly different, (P ≤ 0.05); x-y Different superscripts within columns indicate means are significantly different, (P ≤ 0.10) 
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Figure 5.1. Enumeration of beneficial bacteria from broiler chickens. C. butyricum 
were enumerated from the cecum of broiler chicks at (A) Day 14 and (B) Day 42 post-
hatch. Total LAB was enumerated from the small intestine of broiler chicks at (C) Day 
14 and (D) Day 42 post-hatch. Bifidobacterium were enumerated from the small intes-
tine of broiler chicks at (E) Day 14 and (F) Day 42 post-hatch. Counts are reported as the 
log10 CFU g
-1 digestive contents from 10 broiler chickens per treatment. Different letters 
above bars indicate means are significantly different (P ≤ 0.05) and were separated using 
Duncan’s multiple range. 
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as compared to those fed diets with inclusion levels of 1× containing C. butyricum 
MIYAIRI 588 (Figure 5.1 D).   
5.3.1.3 Bifidobacterium. A significant treatment effect was observed on counts of 
Bifidobacterium in the ileum at Day 14 (P = 0.004) and Day 42 (P < 0.001) post-hatch 
(Figure 5.1 E-F). On Day 14, counts of total Bifidobacterium were greatest when broil-
ers were fed diets containing C. butyricum MIYARI 588. Whereas on Day 42, counts of 
total Bifidobacterium were greatest when broilers were fed the Untreated diet and the 
diet containing 2× and 3× concentrations of C. butyricum MIYARI 588. Total Bifidobac-
terium counts were fewer in broilers administered 1× C. butyricum MIYARI 588 as 
compared to those administered BMD (P = 0.014) and the remaining treatment groups 
(P < 0.001) on Day 42. The dose of C. butyricum MIYAIRI 588 administered was not 
observed to affect the recovery of Bifidobacterium counts on Day 14. However, a signif-
icant effect of C. butyricum MIYAIRI 588 inclusion rate on counts of Bifidobacterium in 
the ileum was observed on Day 42 (P < 0.05), with more Bifidobacterium recovered 
from broiler inclusion levels of 2× and 3× as compared to those fed diets with inclusion 
levels of 1× containing C. butyricum MIYAIRI 588 (Figure 5.1 F).   
5.3.1.4 Gram-positive Cocci. A significant treatment effect was observed on 
counts of total Gram-positive cocci in the ileum at Day 14 (P = 0.004) and Day 42 (P < 
0.001) post-hatch (Figure 5.2 A-B). On Day 14, counts of total Gram-positive cocci 
were greatest when broilers were fed the 1× C. butyricum MIYARI 588 diet, counts of 
total Gram-positive cocci were lowest when broilers were fed the Untreated diet. On 
Day 42, Total Gram-positive cocci counts were greater in broilers administered 3× C.  
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Figure 5.2. Enumeration of bacteria from broiler chickens. Gram-positive cocci were 
enumerated from the small intestine of broiler chicks at (A) Day 14 and (B) Day 42 post-
hatch. Total aerobes were enumerated from the small intestine of broiler chicks at (C) 
Day 14 and (D) Day 42 post-hatch. C. perfringens were enumerated from the small in-
testine of broiler chicks at (E) Day 14 and (F) Day 42 post-hatch. Counts are reported as 
the log10 CFU g
-1 digestive contents from 10 broiler chickens per treatment. Different 
letters above bars indicate means are significantly different (P ≤ 0.05) and were sepa-
rated using Duncan’s multiple range.  
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butyricum MIYARI 588 diets as compared to the BMD (P = 0.006) and Un-
treated (P = 0.038) treatments. Similarly, 2× C. butyricum MIYARI 588 was greater 
than the BMD (P = 0.002) and Untreated (P < 0.001) diets. Additionally, Total Gram-
positive cocci counts were greater in broilers administered 2× and 3× C. butyricum 
MIYARI 588 diets as compared to the 1× C. butyricum MIYARI 588 diet (P < 0.001). 
The dose of C. butyricum MIYAIRI 588 administered was not observed to affect the re-
covery of total Gram-positive cocci on Day 14. However, a significant effect of C. butyr-
icum MIYAIRI 588 inclusion rate on counts of total Gram-positive cocci in the ileum 
was observed on Day 42 (P < 0.05), with more Gram-positive cocci recovered from 
broiler inclusion levels of 2× and 3× as compared to those fed diets with inclusion levels 
of 1× containing C. butyricum MIYAIRI 588 (Figure 5.2 B).   
5.3.1.5 Total Aerobic Bacteria. A significant treatment effect was not observed 
on counts of total aerobic bacteria in the ileum of broilers on Day 14, but fewer aerobic 
bacteria tended to be recovered from broilers fed the Untreated diet as compared to the 
remaining treatment groups (P = 0.060) (Table 5.1 and Figure 5.2 C). However, A sig-
nificant treatment effect was observed on counts of total aerobic bacteria in the ileum of 
broilers on Day 42 (P < 0.001) (Figure 5.2 D). Total aerobic bacteria counts were high-
est from broilers fed the Untreated diet. While, broiler administered 1× C. butyricum 
MIYARI 588 was significantly lower than the remaining treatment groups. The dose of 
C. butyricum MIYAIRI 588 administered was not observed to affect the recovery of to-
tal aerobic bacteria on Day 14. However, a significant effect of C. butyricum MIYAIRI  
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588 inclusion rate on counts of total aerobic bacteria in the ileum was observed on Day 
42 (P < 0.05), with more aerobic bacteria recovered from broilers dosed with levels of 
2× and 3× as compared to those fed diets with inclusion levels of 1× containing C. butyr-
icum MIYAIRI 588 (Figure 5.2 D).   
5.3.1.6 Clostridium perfringens. A significant treatment effect was not observed 
on counts of C. perfringens in the ileum of broilers on Day 14 (P = 0.479) (Figure 5.2 
E-F). A significant treatment effect was also not observed on counts C. perfringens in 
the ileum of broilers on Day 42, but greater C. perfringens tended to be recovered from 
broilers fed the BMD diet as compared to broilers administered C. butyricum MIYAIRI 
588 1× and 2× (P = 0.064). A significant effect of C. butyricum MIYAIRI 588 inclusion 
rate on counts of Clostridium perfringens in the ileum was not observed on Day 21 or 
Day 42 (Figure 5.2 E-F). However, Clostridium perfringens tended to increase with the 
larger dose levels of C. butyricum MIYAIRI 588 on Day 14 and Day 42. 
5.3.2 Feed Conversion 
The effect of the experimental treatments on the feed conversion ratio of broiler 
chickens is summarized in Table 5.2. Overall administration of C. butyricum MIYAIRI 
588 to broilers improved FCR compared to the Untreated diet and were statistically simi-
lar to the BMD treated broilers.  Day 0-14 (P < 0.032), Day 0-29 (P < 0.003), and body 
weight corrected cumulative FCR (P < 0.002) was lower in broilers administered C. bu-
tyricum MIYAIRI 588 when compared to the Untreated control. Also, the two higher 
dosages of the DFM were statistically similar to BMD treated broilers. 
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 A moderate negative correlation (P = 0.013) was observed between counts of 
LAB on Day 14 in the ileum with early FCR (Day 0-14), whereas a weak positive corre-
lation (P = 0.041) was observed between counts of C. butyricum on Day 14 with cumu-
lative FCR (Table 5.3). An additional moderate negative correlation was observed be-
tween counts of total aerobes on Day 14 (P = 0.014) in the ileum with early FCR (Day 0-
14). This data suggesting that increased LAB and total aerobic bacteria were recovered 
from broilers with lower FCR.  
Table 5.2. CBM 588: Feed Conversion of broiler chickens 
Treatment  FCR (Feed:Gain)1  
 Days  
0-14  
Days  
0-29  
Days  
0-42  
cFCR2 
  
BMD Control  1.338b 1.656b 1.772c 1.778b 
Untreated Control (UNT)  1.372a 1.681a 1.812a 1.829a 
CBM 588 1.25  10
8
 cfu kg
-1
  1.347
b 1.648b 1.799ab 1.811a 
CBM 588 2.50  10
8
 cfu kg
-1
  1.354
ab 1.649b 1.785bc 1.777b 
CBM 588 3.75  10
8
 cfu kg
-1
  1.354
ab 1.677a 1.786bc 1.780b 
  
      
P-Value   0.032 0.003 0.011 0.002  
Pooled SEM   0.004 0.004 0.005 0.007 
1 Mortality Adjusted Feed Conversion Ratio (FCR);2 Body Weight corrected Feed Conversion Ratio FCR 
(Feed:Gain); a,b Means within columns with no common superscript differ significantly using Duncan's 
Multiple Range Test (P < 0.05) 
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Table 5.3. CBM 588: Correlation of bacterial counts with FCR 
Bacterial Counts 
(log10 CFU g
-1) 
FCR (Feed:Gain) 
D 0-14 D 15-42 D 0-42 cFCR 
Total LAB1      
Day 14 r 
P 
-0.320* 
0.013 
-0.168 
0.200 
-0.055 
0.675 
-0.077 
0.560 
Day 42 r 
P 
0.027 
0.837 
0.252 
0.052 
0.054 
0.683 
-0.004 
0.974 
Bifidobacterium      
Day 14 r 
P 
0.111 
0.401 
0.012 
0.0926 
-0.062 
0.639 
-0.001 
0.996 
Day 42 r 
P 
-0.027 
0.836 
-0.042 
0.749 
0.005 
0.971 
-0.055 
0.675 
C. perfringens      
Day 14 r 
P 
0.010 
0.939 
0.191 
0.145 
-0.147 
0.262 
-0.084 
0.522 
Day 42 r 
P 
-0.107 
0.415 
0.110 
0.401 
-0.098 
0.455 
-0.009 
0.947 
Total Gram (+)       
Day 14 r 
P 
-0.157 
0.230 
-0.225 
0.083 
0.009 
0.944 
-0.040 
0.761 
Day 42 r 
P 
0.020 
0.880 
-0.008 
0.952 
0.018 
0.889 
-0.058 
0.658 
Total Aerobes       
Day 14 r 
P 
-0.314* 
0.014 
-0.249 
0.155 
-0.115 
0.382 
-0.199 
0.127 
Day 42 r 
P 
0.135 
0.305 
0.160 
0.223 
0.145 
0.269 
0.038 
0.773 
C. butyricum       
Day 14 r 
P 
0.051 
0.700 
-0.009 
0.948 
0.216 
0.097 
0.264* 
0.041 
Day 42 r 
P 
0.186 
0.154 
0.060 
0.646 
0.069 
0.600 
0.094 
0.475 
1LAB, Lactic Acid Bacteria  
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5.4 DISCUSSION 
 The objective of this study was to evaluate the dose response of Direct-Fed C. 
butyricum MIYAIRI 588 administration in broiler chickens as a potential alternative to 
antibiotic growth promoters (AGP). Although AGP have been widely used in production 
of poultry and other livestock, the demand for ABF livestock production has increased 
(15, 350) due to consumer concerns and regulatory limitations (325). Because the 
growth promoting activities of AGP are a result of their effects on the gastrointestinal 
microbiota (134, 351, 352), the microbiota is likely an important target for the develop-
ment of alternatives to AGPs. The administration of Direct-Fed Microorganisms in live-
stock animals has been demonstrated to improve growth performance at levels similar to 
AGPs (16, 156) and reduce colonization of human food-borne and poultry pathogens in 
the gastrointestinal tract of poultry (215-217). Although Clostridium butyricum 
MIYAIRI 588 administration has not been previously evaluated in broilers, other Clos-
tridium butyricum strains has been evaluated. Administration of non-virulent C. butyri-
cum  has been demonstrated to promote populations of Lactobacillus and Bifidobacte-
rium in mice (345) and broilers (346). Additionally, administration of C. butyricum has 
been demonstrated to improve measures of growth performance, antioxidation, immune 
function (332, 346) and meat quality (353) in broiler chickens. Clostridium butyricum 
MIYAIRI 588 was demonstrated to stimulate mucosal immunity (354), inhibit toxin pro-
duction, and growth of enterohemorrhagic E. coli 0157:H7 (348) in mice. CBM 588 has 
also been demonstrated to inhibit the human pathogen Clostridium difficile in vitro 
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(355), and promote growth of lactobacilli and bifidobacteria in humans undergoing Heli-
cobacter pylori eradication treatment (349). In this study, we evaluate the effect of the 
administration of Direct-Fed Clostridium butyricum MIYAIRI 588 on the gastrointesti-
nal microbiota and growth performance of broiler chickens fed diets without AGP. 
 In this study, administration of C. butyricum MIYAIRI 588 improved FCR when 
compared to the Untreated broilers and to levels similar to BMD (Table 5.2). Although 
administration of C. butyricum MIYAIRI 588 has not been evaluated previously in 
broiler chickens, other C. butyricum strains have been demonstrated to improve growth 
performance in chickens (332, 346). Clostridium butyricum is known to produce butyric 
acid (339, 356) which is likely an important mechanism responsible for the probiotic 
benefits of this organism. Administration of butyric acid to broilers has been demon-
strated to increase villus height and surface area in the intestine (342), which is an im-
portant factor in nutrient utilization and growth performance (343, 344). Butyrate pro-
duced by bacteria in the colon of mice have been demonstrated to regulate macrophages, 
favoring a microbiome with butyrate producing bacteria (357). Additionally butyrate has 
been demonstrated to protect in vitro cells from C. jejuni invasion (358), reduce Salmo-
nella colonization in layer chickens (359), and down regulates the expression of Salmo-
nella pathogenicity island 1 gene (360). 
 In this study, administration of Clostridium butyricum MAYAIRI 588 tended to 
increase counts of C. butyricum recovered from broilers as compared to those fed the 
BMD diet on Day 14 and Day 42 (Table 5.1). Counts of C. butyricum were positively 
correlated with FCR. This is more than likely due to overabundance of non-CBM 588 C. 
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butyricum enumerated from broilers fed the Untreated diet, creating a false positive. Alt-
hough C. butyricum were recovered from broilers administered the Untreated diet, it is 
possible that this wild type C. butyricum did not provide any benefits to the host. Fur-
thermore, broilers administered 2× and 3× doses of C. butyricum MIYAIRI 588 had the 
lowest FCR (Table 5.3), yet the Untreated had the highest FCR. Additionally, Clostrid-
ium are predominant members of the cecal microbiota (361-363), which may have added 
background to our C. butyricum selective media, reducing the significance seen between 
treatments. This could explain why a weak positive correlation was seen between C. bu-
tyricum MIYAIRI 588 and cFCR on Day 14. Improved weight gain and reduced FCR 
have been reported previously in broilers administered other strains of C. butyricum 
(346, 364), suggesting the administration of C. butyricum MIYAIRI 588 may potentially 
be an important DFM component of an ABF program. 
Bifidobacterium and LAB are important inhabitants of the gastrointestinal tract 
and are generally recognized as beneficial to intestinal health of poultry (133, 176, 251, 
365). Administration of the 3× and 2× doses of CBM 588 increased levels of the benefi-
cial Bifidobacterium on Day 14 (P = 0.014) and Day 42 (P < 0.001). Additionally, ad-
ministration of Clostridium butyricum MAYAIRI 588 increased counts of Lactic Acid 
Bacteria compared to the broilers administered the Untreated control on Day 14 (P = 
0.014) and 42 (P < 0.001). Similar increases in populations of LAB and Bifidobacterium 
was observed in other studies in which C. butyricum was administered to broiler chick-
ens (345, 346, 361). A moderate negative correlation (r = -0.320, P = 0.013) was de-
tected between total LAB counts on Day 14 with early (Day 0-14) FCR, suggesting an 
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important association between LAB and more efficient feed conversion (Table 5.3). 
LAB cultures, particularly Lactobacillus species, have been used widely as DFMs and 
their administration to broilers has been demonstrated to improve growth performance. 
(94, 157, 176).  
Administration of Clostridium butyricum MAYAIRI 588 increased counts of to-
tal Gram-positive cocci. Gram-positive cocci have a myriad amount of mechanisms of 
resistance to antibiotics (366). Commercial poultry production and processing in the 
United States is known to have antibiotic resistant Enterococcus (367) and Staphylococ-
cus  (368, 369). Due to there being such a broad-spectrum of bacteria that are classified 
as Gram-positive cocci, inferences between FCR can be difficult to elucidate. Further-
more, total Gram-positive cocci is a broad category that includes Lactococcus, which has 
been demonstrated to reduce colitis in mice (370) and Pediococcus, a beneficial microbe 
known to produce antimicrobial peptides against food-borne pathogens (371). Both of 
these Gram-positives are LAB and are generally considered beneficial. An increase in 
Gram-positive LAB in broilers administered the DFM could explain why a significant 
increase was seen in the enumeration of Total Gram-positives. In future studies, qPCR 
could be used to observe specific microbial populations.  
In this study, a negative correlation (r = -0.314, P = 0.014) was detected between 
total Aerobic bacteria counts on Day 14 with early (Day 0-14) FCR, suggesting an im-
portant association between total Aerobes and more efficient feed conversion (Table 
5.3). Fewer total aerobic bacteria tended to be recovered from Untreated broilers than 
broilers administered 1× C. butyricum MIYAIRI 588 on Day 14 (P = 0.060). Although 
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enumeration of total aerobes has been associated with being indicator organisms for hu-
man food-borne pathogens (372), the assumed interrelationships between pathogens and 
total aerobic bacteria may not be appropriate (373), considering aerobic bacteria are 
mostly commensal microorganism. If pathogen isolation is needed, selectively isolating 
pathogenic facultative anaerobes E. coli (374, 375) and Salmonella (376) associated with 
poultry (377) would constitute for a more suitable target in the future. Additionally, no 
significant treatment effect was observed on recovery of C. perfringens. In this study, C. 
perfringens remained in the low ~102 CFU g-1, which is considered normal (378) and 
well below the counts normally associated with Necrotic Enteritis (317). 
 Butyrate produced from C. butyricum MIYAIRI 588 may modulate the gut mi-
crobiota in broilers and promote integrity of the epithelial barrier (379). Although the 
butyrate was not measured in this study, administration of butyrate producing DFMs 
(346, 361) and DFM cocktails with C. butyricum (380) have been demonstrated to in-
crease both LAB and Bifidobacterium counts and improve growth performance of 
broiler chickens. VFAs have been confirmed to regulate intestinal adaptive immune re-
sponse and promote health in mice (381). Furthermore, VFA contribute the maintenance 
of the intestine and prevention of pathogenic organisms (382). Butyrate generated by mi-
crobial fermentation regulates intestinal motility and blood flow (383). Additionally, bu-
tyrate is considered to be an alternative to AGPs, demonstrating increased growth rate 
(384) and reduced fecal shedding and colonization of Salmonella infected broilers (359). 
Mountzouris et al. suggest elevated levels of beneficial bacterial populations stimulate 
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the proliferation and metabolism of bacteria that produce VFAs like butyrate, which may 
explain for probiotic mediated performance (361).  
In this study, we investigated the effect of the dose administration of the DFM C. 
butyricum MIYAIRI 588 on the gastrointestinal microbiota and feed efficiency of broiler 
chickens. We have demonstrated the ability of the DFM to improve feed efficiency and 
modify the gastrointestinal microbiota, suggesting this and other DFMs may serve as al-
ternatives to sub-therapeutic uses of antibiotics in poultry. Administration of C. butyri-
cum MIYAIRI 588 improved FCR in broilers, while promoting beneficial microorgan-
isms LAB and Bifidobacterium in the gastrointestinal tract at Day 14, and reducing C. 
perfringens at day 42 compared to the BMD. We have observed associations with Lactic 
Acid Bacteria, total aerobes, and Clostridium butyricum with feed conversion, suggest-
ing potentially important roles of these organisms in gastrointestinal health or in the gas-
trointestinal fermentation community. Lastly, an increase in short-chain fatty acids pro-
duced by C. butyricum MIYAIRI 588 may explain how DFMs mediate host performance 
and promoted growth of beneficial microbes. Additional research will be required in or-
der to determine the VFA content and the degree to which population of organisms 
should serve as therapeutic targets for the development of DFM products intended to re-
place AGPs. 
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6. CONCLUSIONS 
 
6.1 CONCLUDING REMARKS  
There is a growing body of work investigating the functionality of probiotic and 
prebiotics in human and livestock animal health. While there is strong evidence to sup-
port their efficacy, the complicating factors described in this work provide insight into 
the questions regarding their overall effectiveness. Host-specific, probiotic strain-spe-
cific, and application-specific differences further confound the already complex interac-
tions which occur in the gastrointestinal environment. An understanding of these differ-
ences in research studies in humans and livestock animals is necessary for understanding 
the results of host-specific studies and their broader implications to the science. Addi-
tionally, while probiotics and prebiotics are sometimes viewed mistakenly as a universal 
solution to a wide array of health problems, review of the literature suggests that, similar 
to small-molecule therapeutics, specific probiotic cultures or prebiotic compounds are 
only beneficial when used for specific applications in specific host species. Because of 
the benefits they may provide in both human health and livestock animal production, 
novel applications for probiotics and prebiotics are being developed. Continued research 
as described in other chapters is needed to elucidate specific host, microbe, and environ-
mental interactions important in the gastrointestinal tract. An improved mechanistic un-
derstanding of probiotic and prebiotic functionality in specific host-species contexts will 
lead to improved application of probiotics and prebiotics for the benefit of human and 
animal health and livestock animal production.
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